CN1771255A

CN1771255A - Methods and composition for therapeutic use of RNA interference

Info

Publication number: CN1771255A
Application number: CNA028266625A
Authority: CN
Inventors: M·E·达维斯; G·S·詹森; S·H·潘
Original assignee: Insert Therapeutics Inc
Current assignee: Calando Pharmaceuticals Inc
Priority date: 2001-11-02
Filing date: 2002-11-04
Publication date: 2006-05-10
Anticipated expiration: 2022-11-04
Also published as: CN101259289A; CN100384865C; CN101259289B

Abstract

The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeuticand cosmetic purposes.

Description

The method and composition that is used for RNA interferential therepic use

Background of invention

The structure of cell and biological behaviour are to determine by gene expression pattern in the cell of specified time.For a long time, the interference of genetic expression is considered to the reason that a large amount of diseases produce always, and these diseases comprise cancer, vascular disease, neurone and the endocrinopathy of various ways.Known at present, amplification, disappearance, gene rearrangement, forfeiture or the unconventionality expression pattern that obtains functional mutant form all will cause the abnormal behaviour of disease cell.Unusual genetic expression also is considered to some biology and avoids a kind of defense mechanism that pathogenic agent threatens.

One of main challenge of medical science is the regulation and control target gene expression that extensive multiple physiological response involved.Though in eukaryotic cell, external source imports genetically modified the mistake and expresses simply relatively, is still difficult realization of inhibition of target with the specific gene.The traditional method of inhibition of gene expression comprises site-directed gene disruption, sense-rna or collaborative the inhibition or injection, needs complicated gene to handle, or usually exceeds heavy dose of inhibition of host cell toxicity tolerance level.

It is reticent phenomenon after a kind of special genetic transcription of having described two strands (ds) RNA dependence gene that RNA disturbs (RNAi).The initial trial that utilizes this phenomenon to handle mammalian cell is hampered by the strong and nonspecific antiviral defense mechanism of activated in the long dsRNA molecular process of response experimentally.Gil et al. Apoptosis 2000，5：107-114。But the gene specific RNAi of this field in confirming the synthetic duplex mediate mammalian cell of 21 Nucleotide RNA do not obtained remarkable break-throughs and do not cause on the basis of hereditary antiviral defense mechanism.Elbashir et al. Nature 2001，411：494-498；Caplen et al. Proc Natl Acad Sci 2001，98：9742-9747。Little RNA interfering (siRNA) thus become the analysis gene function strong instrument.The little RNA of chemosynthesis is a kind of approach, and has obtained result likely.The carrier based on DNA that can produce this siRNA in cell is also sought to develop by many research groups.Recently, indivedual research groups have realized this target, and have delivered similar scheme, and these schemes generally include transcribing of bob folder (sh) RNA, and these short hairpin RNAs can effectively be processed and form siRNA in cell.Paddison et al. PNAS2002,99:1443-1448; Paddison et al. Genes﹠amp; Dev2002,16:948-958; Suiet al. PNAS2002,8:5515-5520; And Brummelkamp et al. Science2002,296:550-553.These reports have all been described the method for the siRNA that produces the fixed numerous endogenous and heterogenous expression genes of target specifically.

Summary of the invention

One aspect of the present invention provides a kind of stable breathing prescription of the RNAi of comprising construct, this RNAi construct be configured to be used for will the treatment significant quantity the RNAi construct send by lung or nose and pass lung to the patient.In some embodiment, the RNAi construct is configured to mean diameter less than 20 microns, and more preferably mean diameter is the particulate of 0.5-10 micron.In some embodiment, this particulate is formed by biodegradable polymer.In some embodiment, this particulate is by one or more polymer formation in polymkeric substance, urethane, Mierocrystalline cellulose, poly-butyric acid (butic acid), poly-valeric acid, poly-(lactide-be total to-caprolactone) or its multipolymer of being selected from polysaccharide, diketopiperazine, poly-hydroxy acid, polyanhydride, polyester, polymeric amide, polycarbonate, poly-alkylene, polyvinyl compound, polysiloxane, vinylformic acid and methylacrylic acid.

In some embodiment, this particulate melts encapsulation by solvent evaporation, spraying drying, solvent extraction or heat and forms; And in other embodiments, this particulate is drying or lyophilized form.In other embodiments, the RNAi construct is formulated in the liposome.

Also have in some embodiments, the RNAi construct is configured to the supramolecular complex that comprises the multidimensional derivatized polymers.Preferred supramolecular complex is formed by cationic polymers, such as poly-(L) Methionin (PLL), polyaziridine (PEI), contain beta cyclo dextrin polymer (β CD polymkeric substance) or its multipolymer.More preferred supramolecular complex is by the polymer formation of cyclo-dextrin-modified, for example, has the polyaziridine of cyclo-dextrin-modified of the structure of following formula:

Wherein

For every kind of situation, R independently represent H, low alkyl group, cyclodextrin part or

And

For every kind of situation, m independently represents 2-10, and 000, preferred 10-5,000, perhaps 100-1, an integer in 000.

In some embodiment, the breathing prescription that comprises the RNAi construct comprises propelling agent.

In some embodiment, breathe prescription and be accommodated in metered dose inhaler, Diskus or the jet-propelled spraying gun.In a kind of preferred embodiment, the amount of preparation of RNAi construct provides the treatment significant quantity with 1-10 dosing.

Another aspect of the present invention provides the dosing aerosol dispenser, contains in this divider to be useful on lung or nose send the aerosol pharmaceutical compositions of passing, comprise the prescription breathed of RNAi construct.

The present invention also has another aspect that the method that realizes the whole body administration of RNAi construct is provided, this method comprises by the pulmonary administration mode, give the patient with the prescription breathed of RNAi construct, wherein the amount that absorbed by dark lung of this RNAi construct can realize that sending of this RNAi construct body dose pass.

The present invention also has another aspect to provide to comprise at least a RNAi construct, and the pharmaceutical preparation of pharmaceutical acceptable carrier, and wherein the RNAi construct is configured to and is used for lung or nose and send and pass.This pharmaceutical acceptable carrier is selected from pharmaceutically acceptable salt, ester, reaches the salt of these esters.In some preferred embodiment, the invention provides and comprise this pharmaceutical preparation, and guidance gives said preparation the drug packages of the specification sheets (literal and/or diagram) of human patients, wherein this pharmaceutical preparation comprises at least a RNAi construct, and pharmaceutical acceptable carrier, this RNAi construct is formulated as and is used for lung or nose and send and pass.

Another aspect of the present invention provides a kind of composition, comprise one or more and be formulated in the supramolecular complex, and amount of preparation is enough to weaken by the RNA interference mechanism RNAi construct of the target gene expression in the cell of handling.For example, this RNAi construct is the little RNA interfering (siRNA) that length is preferably 19-30 base pair.Optionally the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.Randomly, the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.In some embodiment, said composition is used in the body or handles cell in vitro.

In some embodiment, it is 20-500nm that supramolecular complex is collected at mean diameter, more preferably in the particle of 20-200nm.

Further illustrate, supramolecular complex can be the multidimensional derivatized polymers that comprises linear polymer or branched chain polymer.Typical polymers is a cationic polymers, as gathering (L) Methionin (PLL), polyaziridine (PEI), containing beta cyclo dextrin polymer (β CD-polymkeric substance) or its multipolymer.In some embodiment, supramolecular complex is by the polymer formation of cyclo-dextrin-modified, for example, has the polyaziridine of cyclo-dextrin-modified of the structure of following formula:

Wherein

And

Another aspect of the present invention provides the method that weakens the cells in vivo expression of target gene, this method comprises the RNAi construct that is formulated in the supramolecular complex, dosage is enough to weaken target gene expression by the RNA interference mechanism, thereby changes growth, survival or the differentiation of the cell of handling.

The present invention also has another aspect to provide to comprise at least a RNAi construct, and the pharmaceutical preparation of pharmaceutical acceptable carrier, and wherein the RNAi construct is formulated in the supramolecular complex.This pharmaceutical acceptable carrier is selected from pharmaceutically acceptable salt, ester, reaches the salt of these esters.In some preferred embodiment, the invention provides and comprise this pharmaceutical preparation, and with the drug packages of specification sheets (literal and/or diagram) that instructs administration human patients said preparation, wherein this pharmaceutical preparation comprises at least a RNAi construct, and pharmaceutical acceptable carrier, wherein the RNAi construct is formulated in the supramolecular complex.

Another aspect of the present invention provides the coating that is applied to medical device surface, this coating comprises the polymeric matrix that inside is dispersed with the RNAi construct, when the intravital site of implanted patient, the RNAi construct discharges in matrix, and changes growth, survival or the differentiation of near the cell of implanting of device.Typical case's medical apparatus comprises screw, plate, packing ring, suture line, the prosthese anchoring device, hobnail, bail, electricity leads, valve, film, conduit, the implantable vessel access port, storage blood bag, blood transfusion tube, the central vein conduit, ductus arteriosus, the blood vessel implant, IABP, heart valve, cardiovascular suture line, artificial heart, pacemaker, heart chamber auxiliary pump, device outside, hemofilter, the hemodialysis assembly, the hemoperfusion assembly, plasma exchange assembly and be suitable for unfolded filter in the blood vessel.Some preferred embodiment provides the support of coating.

In some embodiment, the RNAi construct in the coating is the little RNA interfering (siRNA) that length is preferably 19-30 base pair.Optionally the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.Randomly, this RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

Illustrate, the RNAi construct in the coating weakens and is selected from least a target gene expression in cell cycle protein dependent kinase, c-myb, c-myc, proliferating cell nuclear antigen (PCNA), transforming growth factor-beta (TGF-β), transcription factor nf κ B (NF-κ B), E2F, HER-2/neu, PKA, TGF-α, EGFR, TGF-β, IGFIR, P12, MDM2, BRCA, Bcl-2, VEGF, MDR, ferritin, TfR, IRE, C-fos, HSP27, C-raf and the metallothionein gene.

In some preferred embodiment, the RNAi construct reduces the propagation and/or the migration of smooth muscle cell by inhibition of gene expression.

The present invention also has another aspect to provide to adopt the method for one or more RNAi constructs coating medical apparatus, and this method comprises:

A) preparation is used for the RNAi construct on apparatus for coating surface, makes that this RNAi construct discharged from the surface when this installed the intravital site of implanted patient; And

B) the RNAi construct with preparation is coated on medical device surface,

The medical apparatus that wherein is coated with the RNAi construct has weakened one or more expression of gene near the cell of the device of implanting.

Another aspect of the present invention provides the composition that comprises one or more RNAi constructs, and the RNAi construct is configured to be used for sending in the skin pericardium and passs to animal.In a kind of embodiment, the RNAi construct reducer in the said composition is expressed, and the blood vessel around causing reaching in the infarcted myocardium produces to be increased also/or reduce ischemic injury.Randomly, this RNAi construct is that whole body is available, and weakens one or more expression of gene in the pericardial cavity far-end cell.

In some embodiment, the RNAi construct in the composition is packaged in liposome or associates with liposome.For example, this liposome is to form the formed cationic-liposome of lipid by the positively charged ion vesica.Randomly, in the said composition mean diameter of liposome less than about 200nm.

In other embodiment, the RNAi construct is configured to the supramolecular complex that comprises the multidimensional derivatized polymers in addition.Preferred polymkeric substance is a cationic polymers, as poly-(L) Methionin (PLL), polyaziridine (PEI), contain polymkeric substance (β CD polymkeric substance) or its multipolymer of beta-cyclodextrin.

In some embodiment, the supramolecular complex in the composition is by the polymer formation of cyclo-dextrin-modified, for example, has the polyaziridine of cyclo-dextrin-modified of the structure of following formula:

Wherein

And

In some embodiment, the RNAi construct in the composition is the little RNA interfering (siRNA) that length is preferably 19-30 base pair.Optionally the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.Randomly, this RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.In a kind of preferred embodiment, the said composition administration of human.

In a kind of embodiment, the invention provides and comprise at least a RNAi construct, and the pharmaceutical preparation of pharmaceutical acceptable carrier, the preparation of RNAi construct is used for sending in the skin pericardium passs.This pharmaceutical acceptable carrier can be chosen the salt that is selected from pharmaceutically acceptable salt, ester and these esters wantonly.In some preferred embodiment, the invention provides and comprise pharmaceutical preparation, and guidance gives said preparation the drug packages of the specification sheets (literal and/or diagram) of human patients, wherein this pharmaceutical preparation comprises at least a RNAi construct, and pharmaceutical acceptable carrier, this RNAi construct preparation is used for sending in the skin pericardium passs.

The present invention also has another aspect to provide to be used for sending the method for passing one or more RNAi constructs in skin pericardium endosome, this method comprises the pericardial cavity that RNA i construct prescription is administered to animal, and wherein the amount of the RNAi construct of Cun Zaiing is enough to weaken one or more target gene expression of the animal body inner cell for the treatment of.For example, pericardial cavity is used as sending of RNAi construct and passs storage at.In some embodiment, the RNAi construct of this method is sent by the part and passs to heart and peripheral vascular system thereof.In other embodiments, the RNAi construct of this method is used to reduce the propagation and/or the migration of smooth muscle cell, more preferably is used for the treatment of myocardial infarction.

Another aspect of the present invention provides the composition that comprises one or more RNAi constructs, and this RNAi construct is formulated in the liposome, can weaken target gene expression in the cells in vivo by the RNA interference mechanism.In some preferred embodiment, the RNAi construct is the little RNA interfering (siRNA) that length is preferably 19-30 base pair.Optionally the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.Randomly, this RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.Preferred cell is a mammalian cell, as the human cell.

In some embodiment, the liposome in the composition is to comprise that the positively charged ion vesica forms the cationic-liposome of lipid.In other embodiment, the mean diameter of this liposome is less than about 200nm.

The present invention also has another aspect that the method that weakens target gene expression in patient's cell is provided, this method comprises that the RNAi construct that will be formulated in the liposome gives the patient, dosage is enough to weaken target gene expression by the RNA interference mechanism, thereby changes growth, survival or the differentiation of described cell.In some preferred embodiment, the RNAi construct of this method is the little RNA interfering (siRNA) that length is preferably 19-30 base pair.Optionally the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.Randomly, this RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.The preferred cell of this method is a mammalian cell, as the human cell.

In some embodiment, the liposome of this method is to comprise that the positively charged ion vesica forms the cationic-liposome of lipid.In other embodiment, the mean diameter of this liposome is less than about 200nm.

In some embodiment, the invention provides and comprise at least a RNAi construct, and the pharmaceutical preparation of pharmaceutical acceptable carrier, this RNAi construct is formulated in the liposome.This pharmaceutical acceptable carrier is selected from the salt of pharmaceutically acceptable salt, ester and these esters.In some preferred embodiment, the invention provides and comprise this pharmaceutical preparation, and guidance gives said preparation the drug packages of the specification sheets (literal and/or diagram) of human patients, wherein this pharmaceutical preparation comprises at least a RNAi construct, and pharmaceutical acceptable carrier, wherein the RNAi construct is formulated in the liposome.

Another aspect of the present invention provides the composition that comprises one or more RNAi constructs, and the RNAi construct of preparation is used for electroporation by preparation and enters cells in vivo.For example, this RNAi construct is formulated in supramolecular complex or the liposome.In some embodiment, target cell is epithelial cell or myocyte.

The present invention also has another aspect to provide a kind of to send the method for passing the patient by electroporation with one or more RNAi constructs, this method comprises by electroporation and gives animal with the RNAi construct of capacity that wherein the RNAi construct weakens target gene expression in patient's cells in vivo.For example, the RNAi construct of this method is formulated in supramolecular complex or the liposome.In some embodiment, the cell of this method is epithelial cell or myocyte.

In a kind of embodiment, the invention provides and comprise at least a RNAi construct, and the pharmaceutical preparation of pharmaceutical acceptable carrier, this RNAi construct is used for electroporation by preparation and enters cells in vivo.This pharmaceutical acceptable carrier is selected from the salt of pharmaceutically acceptable salt, ester and these esters.In some preferred embodiment, the invention provides and comprise this pharmaceutical preparation, and guidance gives said preparation the drug packages of the specification sheets (literal and/or diagram) of human patients, wherein this pharmaceutical preparation comprises at least a RNAi construct, and pharmaceutical acceptable carrier, this RNAi construct is used for electroporation by preparation and enters cells in vivo.

Another aspect of the present invention provides the composition of the RNAi construct that comprises one or more preparations, be used to suppress undesirable cell growth in the body, wherein by the RNA interference mechanism, the RNAi construct has reduced pair cell mitotic division and/or has stoped the requisite target gene expression of this apoptosis.

In some preferred embodiment, the RNAi construct of this method is the little RNA interfering (siRNA) that length is preferably 19-30 base pair.Optionally the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.For example, this expression vector is selected from additive type expression vector, integrating expression vector, virus expression carrier.In the another kind of preferred embodiment, the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

In some embodiment, the RNAi construct in the said composition suppresses cell proliferation.Optionally the RNAi construct promotes this apoptosis.

Typical case RNAi construct suppresses target gene, be the expression of oncogene, as c-myc, c-myb, mdm2, PKA-I, Abl-1, Bcl2, Ras, c-Raf kinases, CDC25 Phosphoric acid esterase, cyclin, cell cycle protein dependent kinase, Telomerase, PDGF/sis, erb-B, fos, jun, mos, src or Bcr/Abl fusion gene.

In some embodiment, the RNAi construct is used to handle transformant, as suppressing or weaken the growth of hyperplasia sexual cell, and can be the part to this class cancer therapy.

In other embodiments, the RNAi construct is used to suppress lymphocytic activation, comprises the inflammatory diseases of treatment or epidemic prevention mediation.

Also have in some embodiments, the RNAi construct is used to suppress the propagation of smooth muscle cell, comprises treatment or prevention of restenosis.

Also have in other embodiments, the RNAi construct is used to suppress epithelial propagation (as a composition as cosmetic formulations).

In some embodiment, the RNAi construct in the said composition is formulated in the supramolecular complex.This supramolecular complex is optional to comprise at least a polymkeric substance, for example, contains the polymkeric substance of cyclodextrin.Alternatively, this RNAi construct is packaged in liposome or associates with liposome, for example, forms the formed cationic-liposome of lipid by the positively charged ion vesica.Randomly, have typically less than the about basic single-size of 200nm with RNAi construct compound liposome.

In a kind of preferred embodiment, animal is a human patients.

The present invention also has another aspect that a kind of method that suppresses undesirable cell growth in the body is provided, this method comprises the RNAi construct of the preparation that gives the animal capacity, wherein by the RNA interference mechanism, the RNAi construct has reduced pair cell mitotic division and/or has stoped the requisite target gene expression of this apoptosis.

In some embodiment, the RNAi construct in the composition suppresses cell proliferation.Optionally the RNAi construct promotes apoptosis.

In certain preferred embodiment, target gene is an oncogene, as c-myc, c-myb, mdm2, PKA-I, Abl-1, Bcl2, Ras, c-Raf kinases, CDC25 Phosphoric acid esterase, cyclin, cell cycle protein dependent kinase, Telomerase, PDGF/sis, erb-B, fos, jun, mos, src or Bcr/Abl fusion gene.In some embodiment, cell is a transformant, because of the RNAi construct is used to treat the growth of hyperplasia sexual cell, comprises treatment for cancer.In other embodiments, the RNAi construct is used to suppress lymphocytic activation, comprises the inflammatory diseases of treatment or epidemic prevention mediation.Also have in some embodiments, the RNAi construct is used to suppress the propagation of smooth muscle cell, comprises treatment or prevention of restenosis.Also have in other embodiments, the RNAi construct is used to suppress epithelial propagation (as a composition as cosmetic formulations).

In other embodiments, the RNAi construct of this method is formulated in the supramolecular complex.This supramolecular complex at random comprises at least a polymkeric substance, for example contains the polymkeric substance of cyclodextrin.

Alternatively, the RNAi construct is packaged in liposome or associates with liposome, for example, forms the formed cationic-liposome of lipid by the positively charged ion vesica.At random, have typically less than the about basic single-size of 200nm with RNAi construct compound liposome.

In a kind of preferred embodiment, the animal in this method is human.

Another aspect of the present invention provides and has comprised at least a RNAi construct, and the pharmaceutical preparation of pharmaceutical acceptable carrier, and this RNAi construct is used to suppress undesirable cell growth by preparation.This pharmaceutical acceptable carrier is selected from pharmaceutically acceptable salt, ester, and the salt of these esters.In some preferred embodiment, the invention provides and comprise this pharmaceutical preparation, and guidance gives said preparation the drug packages of the specification sheets (literal and/or diagram) of human patients, wherein this pharmaceutical preparation comprises at least a RNAi construct, and pharmaceutical acceptable carrier, wherein this RNAi construct is used to suppress undesirable cell growth by preparation.In the another embodiment, the invention provides the cosmetic formulations that comprises at least a RNAi construct, this RNAi construct is used to suppress undesirable cell growth by preparation.

The present invention also has another aspect that the method for inducing cell death is provided, this method comprises target cell double-stranded RNA in the donor, maybe can transcribe and have sufficient length to activate the expression vector of the double-stranded RNA that PKR replys in the target cell, this double-stranded RNA is configured to the part of supramolecular complex.

In some preferred embodiment, the length of double-stranded RNA surpasses 35 base pairs, also will more preferably surpass 75,100,200 or even 400 base pairs.In some embodiment, target cell is a mammalian cell, comprises transformant.In some embodiment, supramolecular complex is the multidimensional derivatized polymers that comprises linear polymer or branched chain polymer.Preferred supramolecular complex is formed by cationic polymers, as poly-(L) Methionin (PLL), polyaziridine (PEI), contain the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

In some embodiment, supramolecular complex comprises the polyaziridine of the cyclo-dextrin-modified of the structure with following formula by the polymer formation of cyclo-dextrin-modified:

Wherein

And

The present invention also has another aspect that a kind of method of carrying out medicine commerce is provided, and this method comprises:

A) identify to suppress target cell propagation in the body, and reduce to relate to the RNAi construct of influence of the disease of undesirable target cell propagation;

B) carry out the effectiveness and the toxic treatment signature analysis of the RNAi construct identified in the step a); And

C) preparation comprises one or more are accredited as the RNAi construct with the feature of can receiving treatment through step b) pharmaceutical preparation.

Preferably, the method for carrying out medicine commerce comprises another step, promptly set up the branch assembling system of this pharmaceutical preparation packing to be used to sell, and (randomly) sets up the replenish step of the selling party of this pharmaceutical preparation of marketing.

B) (randomly) carry out the effectiveness and the toxic treatment signature analysis of the RNAi construct identified in the step a); And

C) right that will further develop the RNAi construct is authorized the third party.

The accompanying drawing summary

Fig. 1 shows that the plasmid with the sense strand of the plasmid of encoding green fluorescent protein (GFP) and/or coding siRNA oligonucleotide and antisense strand send and passs to HEK 293-EcR cell.In the opti-MEM of 0.5ml, make one (many) kinds plasmid compound with ratio and the branch's PEI25k-hi-CD polymkeric substance of 15N/P, it is sent pass to cell again.The GFP expression is to measure after adopting one indicated (many) to plant the plasmid transfectional cell relatively.

Fig. 2 shows that β-CD polymkeric substance 4/DNA proportioning and serum condition render a service the influence of (● and ■) and cell survival situation to the transfection in the BHK-21 cell.Employing dotted line and solid line show the transfection results in 10% serum and the serum free medium respectively.Report data be three samples average+/-S.D..

Detailed Description Of The Invention

I. General introduction

The invention provides the method and composition that weakens expression of target gene in the body. Usually, the method comprises that giving the RNAi construct (decides the little RNA interfering (being siRNA) of specific mRNA sequence such as target, or can in cell, produce the nucleic acid substances of siRNA), dosage is enough to the interference mechanism by RNA, as with sequence dependent, PKR not the dependence mode weaken expression of target gene. Particularly the inventive method can be used to change Growth of Cells, survival or differentiation, thereby reaches the purpose for the treatment of and beauty treatment.

One aspect of the present invention relates to uses the expression that the RNAi construct weakens propagation regulatory gene (comprising apoptosis suppressor). This embodiment can be used as the part for the treatment of or beauty therapeutic program, can suppress or reduce at least the growth of undesirable Growth of Cells, especially transformant in the body.

Another aspect of the present invention relates to the RNAi construct for pulmonary administration, as breathing RNAi construct prescription. This prescription can be used to part or systemic delivery RNAi construct, and consist of will be for any multiple indication, as the RNAi construct that is not limited to treat proliferative disease gives patient's short-cut method. Only prove for example that some RNAi composition of the present invention can be used to reduce the expression of vasoconstrictor, or reduces the acceptor levels of this vasoconstrictor, to reduce general and pulmonary hypertension patient's blood pressure.

The present invention also has another aspect to relate to adopt the RNAi construct, the method for sending the mode of passing to treat the patient by medicine in the skin pericardium, and wherein cavum pericardiale effectively is used as sending of RNAi construct and passs storage at. Although this technology effectively, can expect still that it send the part to be handed to heart and peripheral vascular system thereof with especially effective in the systemic delivery of RNAi construct.

For example, in the treatment of miocardial infarction, the invention provides the angiogenic RNAi method of construct that gives, produce to promote blood vessel, thereby and promote in the infarcted myocardium and the recovery of surrounding tissue and/or prevention to its further damage. For example, the inventive method can be used to send the RNAi construct of passing active the protein expression that can suppress negative regulator NF-κ B transcription factor, for example, by suppressing the expression of NF-κ B repressor I κ B, perhaps other any activity that reduces the cell factor that trofermin institute induction of vascular produces in the body of negative regulator. Other target that the RNAi mediation weakens comprises the gene of coding C reactive protein (CRP). CRP can suppress the Angiogenesis by basic endothelial growth factors and VEGF stimulation.

Medicine send to pass also can be used to send and passs the RNAi construct in the pericardium, and this RNAi construct reduces propagation and/or the migration of smooth muscle cell, thereby can be used for treating neointimal hyperplasia, such as ISR, and arthrosclerosis etc. Only prove for example, the inhibition of neointimal hyperplasia can be achieved by giving the RNAi construct, and described RNAi construct weakens c-myb, c-myc, PCNA (PCNA), transforming growth factor-beta (TGF-β), such as the gene expression of the transcription factor of Nuclear factor kappa B (NF-κ B) and E2F. Medicine send and passs to reduce the neointimal hyperplasia in pericardium, the present invention has considered specifically also that the RNAi construct of " on support " send and has passed, or by the RNAi construct directly being coated with the support of at least a portion, or by means of the polymer coating that can discharge this RNAi construct, and realize giving passing.

Another aspect of the present invention relates to the medical apparatus of coating. For example, in some embodiment, the inventive method provides at least one attached cated medical apparatus in surface, and wherein this coating comprises polymer substrate of the present invention and RNAi construct. This coating can be applicable on the surgical operating instrument, as screw, plate, packing ring, suture, prosthese anchoring device, hobnail, bail, electricity lead, valve, film. This device can be conduit, implantable vascular access port, storage blood bag, blood transfusion tube, central vein conduit, arterial duct, blood vessel implant, IABP, cardiac valves, cardiovascular suture, artificial heart, pacemaker, heart chamber auxiliary pump, device outside, hemofilter, haemodialysis assembly, hemoperfusion assembly, plasma removing assembly, and is suitable for the filter of expansion in the blood vessel.

The present invention also has another aspect that the composition of the RNAi construct that suitable electroporation enters cells in vivo is provided, such as electroporation to the epithelium tissue in (skin, mucous membrane etc.) and the muscle (smooth muscle or skeletal muscle).

Another aspect of the present invention, the RNAi construct is formulated in the supramolecular complex, and is suitable as the medicament use, such as essentially no heat source substance. For example, this supramolecular complex can be by comprising L-PEI or contain the cyclodextrin linear polymer, and the multidimensional derivatized polymers of branched polyethylenimine or branched cyclodextrin polymer forms. In some preferred embodiment, with this expression construct and cyclodextrin, send the system of passing formulated together such as the cyclodextrin cell.

The present invention also has another aspect to relate to utilize long dsrna to activate replying of non-sequence dependent dsRNA in some cell, as activating ds-RNA dependence protein matter kinases PKR. What PKR mediated (surpasses 35 base-pairs such as length to long dsRNA, also will be more preferably surpass 39,50,75,100 or even the dsRNA of 200 base-pairs) to reply be a kind ofly mainly to be activated in virus infected cell, and effective growth inhibition albumen of inducing cell death. Described herein for realizing that the composition that the sequence dependenc RNA disturbs can be adjusted for long dsRNA (is enough to activate PKR such as length easily, and the dsRNA molecule of inducing cell death, such as length at 40-1000 base-pair, preferred 100-800 base-pair, scope that also will more preferred 200-500 base-pair is interior) give in the cell that is handed to hope generation cell death. In a kind of embodiment, long dsRNA prescription of the present invention can be used to the kill cancer cell.

II. Definition

For simplicity, hereinafter concentrated the particular term that is applied in this specification, embodiment and the claims.

Term used herein " animal " refers to mammal, preferred mammal such as the mankind. Equally, " patient " or " experimenter " that await the inventive method treatment can refer to human or inhuman animal.

Term " apoptosis " or " apoptosis " refer to not wish or useless cell in grow and other normal biological process during the physiological processes that is eliminated. Apoptosis is the cell death pattern that occurs under normal physiologic conditions, and this cell is the active participant of himself death (" cell suicide "). This phenomenon is common in the most that normal cell renewal and structural equation, embryo form, immunological tolerance induce and keep, during neural growth and the endocrine dependence Telatrophy. Just the cell at apoptosis demonstrates distinctive form and biochemical character. These features comprise film that chromatin agregation, nuclear and cytoplasm cohesion, cytoplasm and nuclear are assigned to the mitochondria that comprises ribosomes, complete form and nuclear matter surround in the vesica (apoptosis body). In vivo, these apoptosis bodies can be identified rapidly and engulf to macrophage or adjacent epithelial cell. The initiation inflammatory reaction has been avoided in the existence of the effective mechanism of apoptotic cell in this removing body. External, apoptosis body and residual cell fragment are final to expand and cracking. The latter stage of cell in vitro death is by titled with term " secondary necrosis ".

" cell ", " host cell " or " recombinant host cell " are the term that is used interchangeably herein. Be to be understood that these terms not only refer to the specific cell of being examined, also refer to offspring or the potential offspring of these cells. Because sudden change or ambient influnence, some modification may occur in the follow-up generation, and this offspring in fact may be not quite identical with its mother cell, but still be included in the category of this term used herein.

" disease association " or " diseases induced " gene refers to that for undesirable cell phenotype it expresses any gene essential or that play an important role. This gene may be the gene with unusual high level expression; May be the gene with unusual low expression level, the expression that wherein changes be with the generation of disease and/or carry out relevant. Disease related gene also refers to have the gene that one (many) plant sudden change or hereditary variation, and the immediate cause of these sudden changes or hereditary variation or the disease cause of disease perhaps is in the linkage disequilibrium state with the gene that causes the disease cause of disease. It is transcribed or translation product may be known or unknown, and may be in normal or abnormal level.

Term used herein " dsRNA " refers to the siRNA molecule, or other has double-stranded feature, and can be processed into the RNA molecule of siRNA in cell, such as the hairpin RNA part.

In addition, if context does not indicate, term " coding " when this term is used by the typical case, also comprises the DNA sequence that is transcribed into the inhibition antisense molecule with referring to comprise the DNA sequence of coded polypeptide.

Term for gene order " expression " refers to transcribing of this gene, and the suitable translation from the mRNA transcription product that obtains to protein. Therefore, the protein expression that should be understood that from the context coded sequence is the result that this coded sequence is transcribed and translated.

" growth conditions " of cell refers to multiplication rate and the differentiation state of this cell.

" immortalized cell " used herein refers to by chemistry, heredity and/or the reformed cell of recombination form, this cell thereby have in the ability of cultivating through still growing behind the unlimited division number of times.

" inhibition of gene expression " refers to be derived from the protein of target gene and/or the shortage (or observable minimizing) on the mRNA product level. The ability that " specificity " has no significant effect other gene of this cell when referring to suppress target gene. Suppress external attribute that the result can be by checking this cell or organism or (introducing such as embodiment hereinafter) or confirmed by the biochemical technology such as RNA solution hybridization, nuclease protection, Northern hybridization, reverse transcription, microarray gene expression monitoring, antibody combination, enzyme-linked immunosorbent assay (ELISA), Western blotting, radioimmunoassay experiment (RIA), other immunization experiment and fluorescence activated cell analysis (FACS).

Term " afunction ", when relating to the gene that RNAi method of the present invention suppresses, this term refers to that the gene expression dose when lacking the RNAi construct compares the minimizing on the gene expression dose.

Phrase used herein " mediate rna i " refers to which RNA (showing) differentiates can be by the ability of this RNAi method degraded, and as in the sequence specific mode, rather than the dsRNA that relies on by non-sequence replys, and replys the degraded that occurs such as PKR.

Term " nose send and passs " refer to by suck and enter via nose in the nose mode with RNAi construct general send and be handed in the patient body.

Term used herein " nucleic acid " refers to such as DNA (DNA), also refers to the polynucleotides of ribonucleic acid (RNA) in the time of suitably. When being applicable to described embodiment, this term also is appreciated that and comprises strand (such as sense or antisense) and double-stranded polynucleotide.

When describing concerning between two DNA zones, " being operably connected " refers to be relative to each other on their functions. For example, if promoter or other transcriptional regulatory sequences can be controlled transcribing of certain coded sequence, just can be operatively connected on this coded sequence.

Term " pharmaceutically acceptable salt " refers to physiology and the acceptable salt of pharmacy in the compound of the present invention, has namely kept the parent compound BA of expectation, and does not obtain the salt of undesirable toxicity effect.

" propagation " used herein and the mitotic cell of " propagation " fingering row.

When the sequence of " protein coding sequence " or " coding " specific polypeptide or peptide refers under being in the control of suitable adjusting sequence, in external or body, transcribed (in the DNA situation) and translated (in the mRNA situation) and be the nucleotide sequence of polypeptide. The border of this coded sequence is defined by being positioned at the terminal initiation codon of 5 ' (amino) and being positioned at terminal translation stop codon of 3 ' (carboxyl). Coded sequence can include, but not limited to the genomic dna sequence in cDNA, protokaryon or the eukaryotic DNA source in protokaryon or eukaryotic mrna source, or even synthetic dna sequence dna. Transcription terminator will be located in 3 ' end of this coded sequence usually.

Term " lung send and passs " and " breathing is sent and is passed " refer to mode by sucking and enter lung via mouth with RNAi construct systemic delivery to patient body.

" recombinant virus " refers to pass through the virus of genetic modification, as by the heterologous nucleic acids construct being added or inserting mode in this virion.

Term used herein " RNAi construct " is to run through the common name that this specification adopts, and this term comprises little RNA interfering (siRNA), hairpin RNA, and other is can be in body cleaved and form the RNA kind of siRNA. RNAi construct herein also comprises the expression vector (being also referred to as the RNAi expression vector) with following function, namely causes the transcription product that can form dsRNA or hairpin RNA in cell, and/or causes the transcription product that can produce siRNA in body.

" RNAi expression vector " (being also referred to as " dsRNA encode plasmid " herein) refers to be used to express the reproducible nucleic acid construct of (transcribing) RNA, and wherein this RNA can produce the siRNA part in the cell of expressing this construct. The transcript unit that this carrier comprises comprises the set of following three kinds of materials, (1) one (many) of performance regulating action plant genetic elements in gene expression, for example promoter, operon or enhancer, these genetic elements are operably connected to (2) and are transcribed and produce double-stranded RNA (two RNA parts of annealing and formation siRNA in cell, maybe can be processed to the single hairpin RNA of siRNA) " coding " sequence, and (3) suitable transcription initiation and terminator sequence. The selection of promoter and other regulating element changes according to the difference of the host cell of planning usually. Usually, the expression vector that recombinant DNA technology is utilized usually is " plasmid " form, namely refers to circular double-stranded DNA ring, is not combined with chromosome with the expression vector that this carrier format exists. In this specification, when plasmid was the most frequently used form of carrier, " plasmid " and " carrier " was used interchangeably. But, plan of the present invention comprises and can bring into play suitable function and subsequently by the expression vector of other form known in the art.

In this expression vector, the regulating element that control is transcribed can be derived from mammal, microorganism, virus or insect genes usually. And can mix in addition usually replication capacity in the host who is given by origin of replication, and the Select gene that helps to identify transformant. Also can use to be derived from the carrier of viruses such as retrovirus, adenovirus.

Term " little RNA interfering " or " siRNA " refer to that length is approximately 19-30 nucleotides, the nucleic acid of more preferred 21-23 nucleotides. This siRNA is double-stranded, and may comprise short jag at each end. Preferably, being positioned at 3 ' terminal jag length is 1-6 nucleotides. This siRNA known in the art can be by chemical synthesis, or is derived from longer double-stranded RNA or hairpin RNA. This siRNA has the similar important sequence with target RNA, thus this siRNA can with target RNA pairing, and cause the sequence-specific degraded of this target RNA by the RNA interference mechanism. Randomly, this siRNA molecule comprises 3 ' hydroxyl.

Term " supramolecular complex " refers to the multidimensional derivatized polymers that formed by at least a polymer. This polymer molecule can be linearity or branch, for example poly-(L) lysine (PLL), polyaziridine (PEI), contain beta cyclo dextrin polymer (β CD-polymer) and copolymer. In some embodiment, the present invention relates to be configured to the RNAi construct of supramolecular complex.

" transcriptional regulatory sequences " is to run through the common name that this specification is used to refer to dna sequence dna, and as inducing or control initial signal that the specific coding sequence transcribes, enhancer, promoter etc., wherein this coded sequence and this transcriptional regulatory sequences are operatively connected.

Term used herein " transduction " and " transfection " are received technology, mean the transgenosis by the nucleic acid mediation, with nucleic acid, such as a kind of expression vector, import in the recipient cell. " conversion " used herein refers to because the cellular uptake of foreign DNA or RNA causes a process of cytogene type change, and for example, this transformant is expressed the RNAi construct. When a kind of nucleic acid construct can be inherited by the filial generation of cell, then this cell " stable transfection " by this nucleic acid construct.

" transformant " used herein refers to that nature changes the cell of unrestricted growth conditions into, and namely they have obtained in cultivation through infinitely dividing the ability that number of times is still grown. According to the forfeiture degree of growth control, transformant can be by characterizing such as knurl, undifferentiated and/or proliferative term. For the object of the invention, term " the conversion phenotype of pernicious mammalian cell " and " conversion phenotype " can include but not limited to, in the relevant phenotypic characteristic of cell transformation following and mammalian cell any one: immortalization, morphology or growth transform, tumorigenicity, prolong as detected growth in cell is cultivated, can in semisolid culturemedium, grow, cause tumor growth in perhaps in immune deficiency or homogenic animal body.

" transient transfection " refers to that foreign DNA is not integrated into the situation in the genome of transfectional cell, as being transcribed into mRNA as additive type DNA, and when being translated into protein.

Term used herein " carrier " refers to a kind of nucleic acid molecules, and this nucleic acid molecules can be transferred to another nucleic acid the part that it has connected. One type carrier is the genome conformity carrier, or " integration vector ", and the type carrier can be integrated in the chromosomal DNA of host cell. The carrier of another kind of type is episomal vector, can be in the nucleic acid of extrachromosomal replication. Gene expression can be directed to the carrier that functionally connects and be called as herein " expression vector ". In this specification, without indicating in addition, " plasmid " and " carrier " is used interchangeably such as context.

III. Typical case RNAi construct

This RNAi construct contains can be under the cell physiological condition, with the nucleotide sequence of the nucleotide sequence hybridization of the mRNA transcription product for the treatment of suppressor (i.e. " target " gene) at least a portion. This double-stranded RNA only needs abundant similar the getting final product to the natural RNA that has mediate rna i ability. Therefore, the present invention has the advantage that can tolerate the sequence variations that may be expected owing to genetic mutation, bacterial strain polymorphism or evolutionary divergence. The nucleotides mispairing number of allowing between target sequence and this RNAi construct sequence is to be no more than one in 5 base-pairs, or is no more than one in 10 base-pairs, or is no more than one in 20 base-pairs, or is no more than one in 50 base-pairs. The mispairing at SiRNA duplex center is the most key, and may substantially destroy the cracking of target RNA. By comparison, the specificity that is positioned at 3 ' of the siRNA chain of target RNA complementation terminal nucleotide pair target identification there is no remarkable effect.

(see Gribskov and Devereux by sequence comparison known in the art and alignment algorithm, Sequence Analysis Primer, Stockton Press, 1991, and the list of references of quoting), and pass through, for example adopt the Smith-Waterman algorithm (such as University of Wisconsin Genetic Computing Group) of the BESTFIT software program realization of default parameters, calculate the percentage difference between the nucleotide sequence, but just sequence optimized homogeneity. Sequence homogeneity between inhibitory RNA and the part target gene surpasses 90%, perhaps even 100% be preferred. Alternatively, the duplex zone of this RNA may function be defined as can with the nucleotide sequence of the part of target gene transcription product hybridization (such as 400mM NaCl, 40mM PIPES pH6.4,1mM EDTA, 50 ℃ or 70 ℃ of hybridization 12-16 hour; Then washing).

Can carry out the generation of RNAi construct by chemical synthesis process or recombinant nucleic acid technology. The endogenous RNA polymerase of the cell of processing can mediate transcribing in the body, and perhaps clone's RNA polymerase can be used to in-vitro transcription. This RNAi construct can comprise the modification to phosphoric acid-sugar backbone or nucleosides, as, reduce the sensitivity to the nucleus enzyme, improve bioavailability, formula property, and/or change other medicines dynamic metabolism characteristic. For example, the phosphodiester bond of natural RNA can be modified to the hetero atom that comprises at least one nitrogen or sulphur. The structural modification of RNA can be trimmed to and allow specific heredity to suppress, and avoids simultaneously generally replying dsRNA. In addition, can modify to block to base the activity of adenosine deaminase. This RNAi construct can obtain by enzymatic or by part/total organic synthesis, can import the ribonucleotide of any modification by the method for external enzymatic or organic synthesis.

The method of chemical modification RNA molecule also goes for modifying the RNAi construct and (for example sees Heidenreich et al. (1997)Nucleic Acids Res.25：776-780；Wilson et al.(1994) J Mol Recog 7：89-98；Chen et al.(1995) Nucleic Acids Res 23：2661-2668；Hirschbein et al.(1997) Antisense Nucleic Acid Drug Dev7:55-61). Only illustrate, can adopt thiophosphate, phosphoramidate, phosphorodithioate, chimeric methyl-phosphonate-di-phosphate ester, peptide nucleic acid, contain the 5-propinyl of oligomer or sugar-modified (such as 2 '-ribonucleotide that substitutes, a-configuration)-pyrimidine modifies the main chain of RNAi construct.

This duplex structure can form by wall scroll self complementary RNA chain or two complementary RNA chains. The formation of RNA duplex can be in cell or outside start. The RNA that can be imported into amount should be able to realize that each cell send at least and pass a copy. The higher dosage (such as each cell at least 5,10,100,500 or 1000 copies) of double-stranded material can produce more efficiently inhibition, and also may be effective to some application-specific than low dosage. Suppress to be sequence specific, suppress because surely be used for heredity with this corresponding nucleotide sequence in RNA duplex zone by target.

In some embodiment, RNAi construct of the present invention is " little RNA interfering " or " siRNA ". The length of these nucleic acid is approximately 19-30 nucleotides, will more preferred length be 21-23 nucleotides also, as on length with corresponding than the fragment that long dsrna obtains by nuclease " cutting ". This siRNA is considered to replenish the nuclease compound, and by matching with particular sequence, this compound is guided to said target mrna. The result is that this said target mrna is by the nuclease degradation in the protein complex. In a kind of particular, length is that the siRNA molecule of 23 nucleotides of 21-comprises 3 ' hydroxyl.

Utilize multiple technologies well known by persons skilled in the art all can obtain siRNA molecule of the present invention. For example, utilize methods known in the art chemical synthesis or restructuring to produce siRNA. For example, can synthesize short sense and antisense RNA oligomer, and it is annealed to form double-stranded RNA structure (Caplen, the et al. (2001) that each end all has 2-nucleosides jagProc Natl Acad Sci USA, 98:9742-9747; Elbashir, et al. (2001) EMBO J, 20:6877-88). Subsequently, as described below, perhaps by passive picked-up, the perhaps selected system of passing of sending just can be with in the direct transfered cell of these double-stranded siRNA structures.

In some embodiment, can obtain the siRNA construct than long dsrna by processing, for example, in the situation that the dicer enzyme exists. In a kind of embodiment, employing be the fruit bat vitro system. In this embodiment, dsRNA mixes with the soluble extract in drosophila embryos source, has produced a kind of associating system. This associating system is maintained at dsRNA, and can be processed to length be about 21 under the condition of the RNA molecule of about 23 nucleotides.

But utilize all this siRNA molecules of purifying of multiple technologies well known by persons skilled in the art. For example, utilize gel electrophoresis purifying siRNA. Alternatively, can utilize non-denaturation method, such as non-this siRNA of sex change column chromatography purification. In addition, can utilize the method purifying siRNA that chromatography (such as the size exclusion chromatography), glycerine gradient are centrifugal, adopt the affinity purification of antibody.

In some preferred embodiment, at least one chain of this siRNA molecule has a 3 ' jag, and its length is about 1 to about 6 nucleotides, but also can be the length of 2-4 nucleotides. More preferred 3 ' jag length is 1-3 nucleotides. In some embodiment, a chain has a 3 ' jag, and another chain perhaps also has a jag then by blunt end. The jag length of every chain can be identical or different. For further strengthening the stability of siRNA, can carry out anti-degraded stabilisation to this 3 ' jag. In a kind of embodiment, by comprising purine nucleotides, such as adenosine or guanylic acid to stablize RNA. Alternatively, substitute pyrimidine nucleotide by the analog of modifying, as can substituting uridylate 3 ' jag by 2 '-deoxythymidine, and do not affect the effectiveness of RNAi. The shortage of 2 ' hydroxyl has significantly strengthened the nuclease resistance of jag in the tissue culture medium (TCM), and may be favourable in vivo.

In other embodiments, the form of RNAi construct is long dsrna. In some embodiment, the RNAi construct comprises 25,50,100,200,300 or 400 bases at least. In some embodiment, RNAi construct length is 400-800 base. This double-stranded RNA is digested in cell, as produce siRNA sequence in cell. But, utilizing long dsrna always ineffective in the body, may be because the dsRNA of non-sequence dependent replys caused poisonous effect. In these embodiments, be preferred but utilize the part to send the medicament of the system of passing and/or reduce disturbance element or PKR effect.

In some embodiment, the form of RNAi construct is hairpin structure (being named as hairpin RNA). This hairpin RNA can be that external source is synthetic, or the rna plymerase iii promoter transcription forms in the body. At for example Paddison et al..,Genes Dev，2002，16：948-58； McCaffrey et al.， Nature，2002，418：38-9；McManus et al.， RNA， 2002，8：842-50；Yu et al.， Proc Natl Acad Sci USA, the example for preparing and this hairpin RNA is applied in gene silencing in the mammalian cell has been described in the document of 2002,99:6047-52. Preferably, this hairpin RNA is by engineering design in cell or in the animal body, to guarantee the continuous and stable inhibition of target gene. The hairpin RNA of processing in cell known in the art can produce siRNA.

Also have in other embodiments, adopt plasmid to send and pass double-stranded RNA, such as the double-stranded RNA as transcription product. In these embodiments, plasmid is designed to comprise two " coded sequences " of the sense and antisense chain that corresponds respectively to this RNAi construct. These two coded sequences can be identical sequences, as, be positioned at its flank by two inverted promoters, perhaps can be in respectively two independent startup transcribe control under two independent sequences. After this coded sequence was transcribed, the base pairing of complementary RNA transcription product had just formed double-stranded RNA.

PCT application WO01/77350 has described a kind of for the bidirectional transcription transgenosis, to produce the typical carriers of identical genetically modified sense and antisense rna transcription product in eukaryotic. Correspondingly, in some embodiment, the invention provides the recombinant vector with following specific characteristic: comprise virus replication, be arranged with two overlapping transcript units on two rightabouts in this replicon, and be positioned at a genetically modified flank, this transgenosis is used to our interested RNAi construct, and what wherein these two overlapping transcript units can be in host cell produces the sense and antisense rna transcription product from identical transgenic fragment.

IV. Representative formula

RNAi construct of the present invention also can with the mixture of other molecule, molecular structure or compound, for example the fixed molecule of liposome, polymer, acceptor target, oral, rectum, part or other prescription mixes, encapsulation, in conjunction with or associate via alternate manner, with auxiliary picked-up, distribute and/or absorb. RNAi construct of the present invention may be provided in the prescription that also comprises penetration enhancer, carrier compound and/or transfection agents.

Told about preparation and passed the RNAi construct applicable to sending, the representative United States Patent (USP) of the method for the especially picked-up of siRNA molecule, distribution and/or absorption auxiliary formula include but not limited to U.S.5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; With 5,595,756.

RNAi construct of the present invention also comprises the salt of any pharmaceutically acceptable salt, ester or these esters, perhaps other is any on to the basis that comprises human animals administer, and the compound of its BA metabolin or residue can (directly or indirectly) be provided. Correspondingly, for example, the disclosure content also relates to the pharmaceutically acceptable salt of RNAi construct and siRNA, the pharmaceutically acceptable salt of this RNAi construct, and other bioequivalence thing.

Pharmacy can be accepted base addition salts and be formed by metal or amine, such as alkali and alkaline-earth metal or organic amine. Being used as cationic metal example is sodium, potassium, magnesium, calcium etc. Suitable amine example is N, and NI-dibenzyl-ethylenediamin, chloroprocanine, choline, diethanol amine, dicyclohexylamine, ethylenediamine, N-METHYL-ALPHA-L-GLUCOSAMINE and procaine (are seen for example Berge et al., " Pharmaceutical Salts, "J.of Pharma Sci., 1977,66,1-19). The base addition salts of acid compound is by conventional methods, makes the acid of free form contact rear generation salt with the alkali of capacity appointment, and prepared. Free acid can contact with acid by making salt, and is regenerated after separating in a usual manner this free acid. Its corresponding salt of this free acid is in some physical attribute, such as slightly variant aspect the solubility in polar solvent, but then, and for the purposes of this invention, its corresponding free acid equivalence of this salt. " medicine addition salts " used herein comprises the pharmaceutically acceptable salt of arbitrary component acid form in the present composition. This comprises the organic or inorganic hydrochlorate of amine. Preferred hydrochlorate is hydrochloride, acetate, salicylate, nitrate, phosphate. Those skilled in the art also know other suitable pharmaceutically acceptable salt, comprise multiple inorganic and organic acid basic salt.

For the siRNA oligonucleotides, the preferred embodiment of pharmaceutically acceptable salt include but not limited to (a) by the cation such as sodium, potassium, ammonium, magnesium, calcium, such as the polyamines of spermine and spermidine, waits the salt of formation; (b) acid-addition salts that is formed by the inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid etc.; (c) salt that is formed by the organic acid such as acetic acid, oxalic acid, tartaric acid, butanedioic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acids, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid etc.; (d) salt that is formed by the element anion such as chlorine, bromine and iodine.

A. Supramolecular complex

In some embodiment, RNAi construct of the present invention is configured to the part of " supramolecular complex ". Further prove for example, this RNAi construct can contact with at least a polymer, form a kind of synthetic, subsequently, under the condition that is enough to form the supramolecular complex that comprises this RNAi construct and multidimensional derivatized polymers, process the polymer of this synthetic. This polymer molecule can be linearity or branch. Correspondingly, one group of mixture that two or more polymer molecules can be linearity, branch or linearity and branched polymer. This synthetic can be by any proper method preparation known in the art. For example, simply contact, mix or disperse with polymer by making this RNAi construct, just can form this synthetic. Also can be possible identical or different by making, and can under the existence condition of this expression construct, form the monomer polymerization of linearity or branched polymer, and prepare this synthetic. Can adopt at least a part further to modify this synthetic, perhaps opposite as guiding the cellular uptake of this expression construct, affect this expression construct tissue or cell in vivo and distribute. This synthetic can be the form of any appropriate, and preferred form is particle.

In some preferred embodiment, RNAi construct of the present invention is formulated in cationic polymer. Typical case's cationic polymer comprises poly-(L) lysine (PLL) and polyaziridine (PEI). In some preferred embodiment, expression construct of the present invention is formulated in containing beta cyclo dextrin polymer (β CD polymer). β CD-polymer can form polycomplex with nucleic acid, and the cell cultivated of transfection. This β CD polymer can be for example by being synthesized diaminourea-cyclodextrin monomer A and imidodicarbonic diamide ester comonomer B condensation. Cyclodextrin is the cyclic polysaccharide that contains naturally occurring D (+)-glucopyranose unit in α-(Isosorbide-5-Nitrae) key. Modal cyclodextrin is for containing respectively alpha-cyclodextrin, beta-schardinger dextrin-and the γ cyclodextrin of 6,7 or 8 glucopyranose units. Having described in such as the people's such as Gonzalez PCT application WO00/01734 and Dayis PCT application WO00/33885 to be adjusted for sending the classical ring dextrin of passing RNAi construct of the present invention to send the system of passing easily.

In some embodiment, this supramolecular complex is collected in the particle, and for example, average diameter is 20-500 nanometer (nm), also the particle prescription of 20-200nm more preferably.

B. Other cation, non-lipid prescription

In some embodiment, this RNAi construct is provided in cation, the non-lipid carrier, and is formulated the aerosol that is applied in via respiratory tract and send and pass. Adopt poly-(aziridine) and can in atomization process, cause the transfection of high-caliber lung and improve stability such as the macromolecular prescription of dsRNA and dsRNA-coding plasmid. PEI-nucleic acid prescription also can demonstrate the high level specificity to lung.

Except adopting PEI preparation RNAi construct, the present invention also imagines the polymer of using cyclo-dextrin-modified, such as the polyaziridine of cyclo-dextrin-modified. In some embodiment, this polymer has following structural formula:

Wherein

And

For every kind of situation, m independently represents 2-10, and 000, preferred 10-5,000, a perhaps integer in 100-1,000.

In some embodiment, to about at least 1%, more preferably about at least 2%, perhaps about at least 3%, until about 5% or even 10% may be the nitrogen-atoms of primary amine, what R represented is cyclodextrin part (being two kinds of situations that R represents H), and for the cyclodextrin part, then really not so.

In some embodiment, calculate by weight, cyclodextrin has partly formed polymer about at least 2%, 3% or 4% of cyclo-dextrin-modified, until 5%, 7%, even 10%.

In some embodiment, calculate by weight, about at least 2%, 3% or 4% in the polymer, until 5%, 7%, even 10% aziridine subunit is partly modified by cyclodextrin.

Have easily the polyaziridine copolymer that the amino substituted radical of nucleophilic of derivatization partly occurs with cyclodextrin and also can be used to prepare the polymer of the interior cyclo-dextrin-modified of category of the present invention.

The classical ring dextrin partly comprises the circulus that mainly is comprised of 7-9 sugar moieties, such as cyclodextrin and oxidized cyclodextrin. Cyclodextrin is the optional coupling part that forms covalent bond between circulus and the main polymer chain that is included in partly, contain 1-20 atom in the preferred chain, such as alkyl chain, comprise dicarboxylic acid derivatives (such as glutaric acid derivatives, succinic acid derivative etc.), with the isoalkyl chain, such as few glycol chain.

C. The liposome prescription

In some embodiment, the invention provides to comprise and be packaged in liposome or the dsRNA that otherwise associates with liposome or the composition of dsRNA-coding plasmid. Only prove for example, can utilize polycation condensing agent condensation dsRNA part or dsRNA-coding plasmid, and it is suspended in the aqueous culture medium of LIS, Cationic Vesicles forms lipid and has just formed cationic-liposome. The ratio of capable of regulating Liposomes and plasmid is to obtain maximum transfection effect. The ratio of nanomole Liposomes/microgram plasmid usually surpasses 5, but less than 25, preferably surpasses 8, but less than 18, more preferably surpasses 10, but less than 15, highly preferred 12-14. This compound preferably has typically less than about 200nm, and the size of the basic homogeneous in the 50-200nm scope (namely dimensionally ± 20%, preferred ± 10%, more preferred ± 5%) preferably.

The lipid vesicle that liposome used herein refers to have the external lipid shell and is closed with hydrophily inside, this external lipid shell typically is formed on one or more double-layers of lipoid. In a kind of preferred embodiment, this liposome is to form lipid by the Cationic Vesicles between about 20-80 mole percent, becomes neutral vesica to form lipid with all the other, and/or the cationic-liposome that forms of other component. " vesica formation lipid " used herein refers to any amphoteric lipid hydrophobic and that polar head-group regiment headquarters divides that has, and such as phosphatide institute illustration, himself can form double-deck vesica automatically in water. It is the diacyl chain lipid that preferred vesica forms lipid, and such as phosphatide, its acyl chain length typically is about 14-22 carbon atom, and has variable degree of unsaturation.

It is that under the pH4-9 condition, the polar head group has the lipid of clean positive charge at operation pH that Cationic Vesicles forms lipid. Representative instance comprises phosphatide, and such as phosphatidyl-ethanolamine, its polar head group is by positively charged moiety, derives the lipid DOPE (LYS-DOPE) that is for example derived by 1B (Guo, et al., 1993) such as lysine as illustration. This lipoids also comprises glycolipid, as has cerebroside and the gangliosides of cation polar head group.

It is cholesterine amine and relevant cation sterol that applicable another kind of Cationic Vesicles forms lipid. Typical case's cation lipid comprises 1,2-, two oil base oxygen base-3-(three methylaminos) propane (DOTAP); N-[1-(the two tetradecyloxyanilines of 2,3-) propyl group]-N, N-dimethyl-N-ethoxy ammonium bromide (DMRIE); N-[1-(2,3 ,-two oil base oxygen bases) propyl group]-N, N-dimethyl-N-ethoxy ammonium bromide (DORIE); N-[1-(2,3-, two oil base oxygen bases) propyl group]-N, N, N-trimethyl ammonium chloride (DOTMA); 3 β [N-(N ', N '-dimethylamino ethane) carbamyl] cholesterine (DC-Chol); And dimethyl dioctadecyl ammonium (DDAB).

The rest part of this liposome forms lipid by neutral vesica and forms, and meaning vesica formation lipid does not have net charge, perhaps may comprise the lipid that has negative charge in the polar head group of small proportion.This lipoids also comprises phosphatide, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), sphingomyelin (SM), cholesterol, cholesterin derivative and other no electric charge sterol.

Above-mentioned lipid is commercial available, or gets according to disclosing the method preparation.Other lipid that the present invention includes is a glycolipid, as cerebroside and Sphingolipids,sialo.

In a kind of embodiment of the present invention, dsRNA or dsRNA-coding plasmid-lipidosome mixture comprise that having with the hydrophilic polymer chains is the liposome of top coat, and this coating can effectively prolong the blood circulation time of this plasmid/liposome complex.Suitable hydrophilic polymer comprises cyclodextrin (CD), polyoxyethylene glycol (PEG), poly(lactic acid), polyglycolic acid, polyvinylpyrrolidone, Ju Jia oxazolin, Ju ethyl oxazoline, poly-hydroxypropylmethyl acrylamide, PMAm, polydimethylacrylamiin, and the deutero-Mierocrystalline cellulose, as Walocel MT 20.000PV or Natvosol.Preferred hydrophilic polymer chains is polyoxyethylene glycol (PEG), and preferred PEG chain molecular weight is 500-10,000 dalton, more preferably 1,000-5,000 dalton.This hydrophilic polymer may be at water and non-aqueous solvent, as all having solubility in the chloroform.

This coating is about to phosphatide or other diacyl chain lipid and is included in the vesica formation lipid, and adopt this polymer chain that its head group is derived preferably by following method preparation.Prepare this lipid, and by its typical method that forms polymer-coated liposome at U.S.Pat.Nos.5, describe to some extent in 013,556 and 5,395,619, be hereby incorporated by.

Be to be understood that, hydrophilic polymer can be stably and this lipid coupling, or via a labile bond coupling, this labile bond makes this polymer-coated plasmid-lipidosome mixture can be in blood flow cycle period, or just breaks away from after being positioned target site or " release " hydrophilic polymer coating.Hydrophilic polymer, especially polyoxyethylene glycol (PEG), can help to discharge this polymer chain to reply the key of stimulator by one, form on the lipid attached to vesica, for example this literary composition among WO 98/16202, the WO 98/16201 incorporated by reference, and Kirpotin, people such as D. (FEBS Letters, 388:115-118 (1996)) have all described this situation.

In a kind of embodiment, but release key is by the suitable releasing agent of administration, or under the selectivity physiological condition, but as under enzyme or reductive agent existence condition and cleaved chemistry release key.For example, esterase or peptide enzymatic lysis ester bond and peptide bond.Disulfide linkage is the reductive agent by administration such as gsh or xitix, or the reductive agent by existing in the body, as is present in the halfcystine in blood plasma and the cell and is able to cracked.

But other release key comprises the responsive key of pH and is exposed to glucose, light or just cracked key when hot.For example, hydrophilic polymer chains can be attached on the liposome by the responsive key of pH, and this plasmid-lipidosome mixture fixed on certain site by target, and as tumor area, the pH value in this site is this pH sensitivity key of cracking effectively, and the release hydrophilic chain.The responsive key of typical case pH comprises acyloxy alkyl oxide, acetal and ketal key.In another example, the cleavable key is a disulfide linkage, is widely used in referring to linkage containing sulfur herein.Linkage containing sulfur can be synthesized, and with the unstable degree that realizes setting, and comprises disulfide linkage, mixed sulfide-sulfone key and thioether-sulfoxide key.In these three kinds of keys, least susceptible is in thiolysis for disulfide linkage, and thioether-sulfoxide key is susceptible the most then.

But this release key helps to adjust the speed that the hydrophilic polymer fragment discharges from liposome complex.For example very unsettled disulfide linkage can be used to target and decide blood cell or endotheliocyte, and is approaching because these cells are easy to, and the short liposome blood circulation life-span is enough.Another extreme aspect when target is tumor tissues or other organ, arrives at intended target for making mixture, needs the long liposome blood circulation life-span usually, at this moment just can adopt lasting or stable disulfide linkage.

But make hydrophilic polymer chains be typically the change of environment attached to the cleaved in vivo reason of the release key on the liposome, for example, this liposome arrives the specific site of low slightly pH, as the tumor tissues zone, or have the site of reductive condition, in the situation as the anoxic tumour.Intravital reductive condition also can be achieved by certain reductive agent of administration, such as xitix, halfcystine or gsh.The cleavable key is to outside stimulus, such as also may be destroyed in the replying of light or heat.

In the another embodiment, liposome complex comprises that effectively specificity is attached to treatment institute at the affine part on the target cell or the part that leads.This part can be attached to surface of liposome, or the end of hydrophilic polymer chains.As PCT application Nos.WO US94/03103, WO98/16202 and WO 98/16201 are described, and typical part comprises antibody and is used for the part etc. of specific combination target cell surface receptor.This part also can be the hydrophobic fragment that helps this mixture and target cell fusion.

The polycation condensing agent that is used to condensation dsRNA and dsRNA-coding plasmid can be multiple charged cationic polymers, and biological polymer preferably, as spermidine, spermine, polylysine, protamine, total histone, such as the particular group protein ingredient of H1, H2, H3, H4, and other polycation polypeptide, also can comprise bioavailable polymer, as PXB.Should be appreciated that the form that these polycation condensing agents can be utilized is free alkali or salt, for example, protamine sulfate and polylysine hydrobromate.In a kind of preferred embodiment, the polycation condensing agent is a histone, and the indication histone comprises total histone or particular group protein ingredient herein.

In some embodiment, the hydrophobic fragment in the polymer-lipid binding substances is the hydrophobic polypeptides sequence.Preferably, this peptide sequence is by about 5-80, and more preferably 10-50 most preferably is 20-30 nonpolar and/or aliphatic/aromatic amino-acid residue composition.But the fusion of some tunicate virus of these sequence effectively starts and host cell, these viruses comprise parainfluenza virus, such as Sendai virus, simian virus-5 (SV5), Measles virus, Avian pneumo-encephalitis virus (NDV) and respiratory syncytial virus (RSV).Other example comprises the human retrovirus, and such as human immunodeficiency virus-1 (HIV-1), i.e. the pathogenic agent of AIDS can be by the fusion cells infected of this virus tunicle and host cell plasma membrane.Fusion takes place under physiological (promptly neutral) pH condition, and this viral genetic (nucleocapsid) just is injected in the tenuigenin part of host cell then.

D. The prescription of part guiding

In some embodiment, supramolecular complex of the present invention and liposome can associate with one or more parts, this part can effectively be attached to specific cells surface protein or the matrix on the target cell, thereby help this mixture catching to target cell, in some situation, can strengthen the picked-up of cell to this RNAi construct.Only prove for example, be applicable to supramolecular complex of the present invention and liposome target fixed listed to the part example such as the following table of particular cell types.

Part	Acceptor	Cell type
Part	Acceptor	Cell type	Folic acid	Folacin receptor	Epithelial cancer, bone marrow stem cell
Water-soluble vitamins	Vitamin receptor	Various kinds of cell	Folic acid	Folacin receptor	Epithelial cancer, bone marrow stem cell
Water-soluble vitamins	Vitamin receptor	Various kinds of cell	The phosphoric acid Vitamin B6	CD4	The CD4+ lymphocyte
Lipophorin	LDL	Liver cell, vascular endothelial cell	The phosphoric acid Vitamin B6	CD4	The CD4+ lymphocyte
Lipophorin	LDL	Liver cell, vascular endothelial cell	Regular Insulin	Insulin receptor
Transferrins,iron complexes	TfR	Endotheliocyte	Regular Insulin	Insulin receptor
Transferrins,iron complexes	TfR	Endotheliocyte	Semi-lactosi	Asialoglycoprotein receptor	Liver cell
Sialic acid-Lewisx	E, P select albumen	Activated endothelial cells	Semi-lactosi	Asialoglycoprotein receptor	Liver cell
Sialic acid-Lewisx	E, P select albumen	Activated endothelial cells	Mac-1	L selects albumen	Neutrophilic leukocyte, white corpuscle
VEGF	Flk-1、2	The tumour epithelial cell	Mac-1	L selects albumen	Neutrophilic leukocyte, white corpuscle
VEGF	Flk-1、2	The tumour epithelial cell	Basis FGF	The FGF acceptor	The tumour epithelial cell
EGF	The EGF acceptor	Epithelial cell	Basis FGF	The FGF acceptor	The tumour epithelial cell
EGF	The EGF acceptor	Epithelial cell	VCAM-1	a ₄b ₁Integrin	Vascular endothelial cell
ICAM-1	a _Lb ₂Integrin	Vascular endothelial cell	VCAM-1	a ₄b ₁Integrin	Vascular endothelial cell
ICAM-1	a _Lb ₂Integrin	Vascular endothelial cell	PECAM-1/CD31	a _vb ₃Integrin	Vascular endothelial cell, activatory thrombocyte
Osteopontin	a _vb ₁Integrin a _vb ₅Integrin	Endotheliocyte in the atheromatous plaque and smooth muscle cell	PECAM-1/CD31	a _vb ₃Integrin	Vascular endothelial cell, activatory thrombocyte
Osteopontin	a _vb ₁Integrin a _vb ₅Integrin		The RGD sequence	a _vb ₃Integrin	Tumor endothelial cell, vascular smooth muscle cell
HIV GP			The RGD sequence	a _vb ₃Integrin	Tumor endothelial cell, vascular smooth muscle cell
HIV GP	120/41 or GP120	CD4	The CD4+ lymphocyte

E. Can breathe the RNAi construct

Another aspect of the present invention provides and has been applicable to and send the aerosol of passing to respiratory tract with the RNAi construct.Respiratory tract comprises air flue, downtake, wherein goes up air flue and comprises oropharynx and larynx, and downtake comprises tracheae and through segmental bronchus and bronchiolar branch.Last air flue and downtake are collectively referred to as the conductivity air flue.Bronchiolus terminalis then is divided into the final respiratory region of feeding, i.e. the alveolar bronchiole of alveolar or dark lung.

It seems that in view of the above inhalation can be oral and/or nasal administration.Be applicable to that aerosol send the pharmaceutical device example of passing to comprise metered dose inhaler (MDI), Diskus (DPI) and jet-propelled spraying gun.For example, United States Patent (USP) 5,756,353,5,858,784 and PCT application WO98/31346, WO98/10796, WO00/27359, WO01/54664, WO02/060412 in described to be adjusted easily and be used to send the typical inhaling type nucleic acid of passing RNAi construct of the present invention to send the system of passing.United States Patent (USP) 6,294,153,6,344,194,6,071,497 and PCT application WO02/066078, WO02/053190, WO01/60420, WO00/66206 in described and can be used for sending other aerosol formulations of passing double-stranded RNA.In addition, as Templin et al., Antisense Nucleic Acid Drug Dev, 2000,10:359-68; Sandrasagra etal., Expert Opin Biol Ther, 2001,1:979-83; Sandrasagra et al., Antisense Nucleic Acid Drug Dev, 2002,12:177-81 is described, can will be applicable to that inhaling type send the method for passing other oligonucleotide (as antisense oligonucleotide) to be adjusted into and is applicable to the method for passing the RNAi construct of sending.

Human lung can several minutes in the time of a few hours, remove or degraded can be by the deposition gas colloidal sol of hydrolytic rupture rapidly.In last air flue, the ciliate epithelial cell helps " mucous membrane cilia activity ladder ", just can remove the particle that exists from air flue to the mouth direction by it.As Pavia, D., " LungMucociliary Clearance ", Aerosols and the Lung: Clinical and Experimental Aspects, Clarke, S.W. and Payia, D., Eds., Butterworths, London, described in 1984.In dark lung, pulmonary alveolar macrophage can just be engulfed it after the particle deposition soon.As Warheit et al., Microscopy Res.Tech., 26:412-422 (1993) and Brain, J.D., " Physiology and Pathophysiology of Pulmonary Macrophages ", The Reticuloendothelial System, S.M.Reichard and J.Filking, Eds., Plenum, New.York., pp.315-327, described in 1985.Dark lung or alveolar all are the used aerocolloidal major objectives of suction therapeutic of systemic delivery RNAi construct.

In the certain preferred embodiments, when especially wishing to realize the systemic doses administration of RNAi construct, aerosolized RNAi construct is configured to particulate.Diameter is that the particulate of 0.5-10 micron can penetrate lung, and by most of natural cover for defense.By the desired mean particle dia of throat less than 10 microns; When avoiding being breathed out, desired mean particle dia is more than or equal to 0.5 micron.

In some preferred embodiment, RNAi construct of the present invention is formulated in the supramolecular complex, and as mentioned above, its diameter is the 0.5-10 micron, and can be combined in the particle that diameter is the 0.5-10 micron.

In other embodiments, RNAi construct of the present invention is provided at through suitably preparing the suitable lung in back and send in the liposome of passing or supramolecular complex (as mentioned above).

(i) be used to form the polymkeric substance of particulate

Except that above-mentioned supramolecular complex, also have a large amount of other polymkeric substance can be used to form particulate.Term used herein " particulate " comprises microballoon (evenly spheroid), microcapsule (having a core and polymeric outer layer) and irregularly shaped particle.

Polymkeric substance preferably in the regular hour section or relatively in the near future, in common 1 year, more typical some months, also will more typical several days in several weeks, can be in time by biological degradation and discharge the polymkeric substance of RNAi construct.Biological degradation both can refer to breaking of particulate, promptly formed the disassociation of the polymkeric substance and/or the polymkeric substance itself of particulate.Its occurrence cause can be for following several, change to the pH that it discharges the site after by administration from the carrier at particle place, situation as diketopiperazine, hydrolysis, as the situation of poly-hydroxy acid, such as the diffusion of the ion of calcium from particulate, as by such as the polymer ions of alginates in conjunction with formed particulate situation in, and the enzyme effect, in the polysaccharide and protein situation as majority.In some situation, linear release may be the most useful, although pulse release or " a large amount of discharge " also may obtain more efficiently result in other situation.

Representational synthetic materials is: diketopiperazine, such as poly(lactic acid), the poly-hydroxy acid and the multipolymer thereof of polyglycolic acid, polyanhydride, polyester such as poe, polymeric amide, polycarbonate, such as polyethylene, polypropylene, polyoxyethylene glycol, polyethylene oxide, the poly-alkylene of polyethylene terephthalate, such as polyvinyl alcohol, polyvinyl ether, polyvinyl ester, polyvinyl halides, polyvinylpyrrolidone, polyvinyl acetate, polyvinyl chloride, the polyvinyl compound of polystyrene, polysiloxane, the polymkeric substance of vinylformic acid and methylacrylic acid, comprise polymethylmethacrylate, polyethyl methacrylate, poly-n-butyl methacrylate, polyisobutyl methacrylate, the own ester of polymethyl acrylic acid, polymethyl acrylic acid isodecyl ester, polylauryl methacrylate, the polymethyl acid phenenyl ester, polymethyl acrylate, the polyacrylic acid isopropyl ester, polyisobutyl acrylate, polyoctodecyl acrylate, urethane and multipolymer thereof, Mierocrystalline cellulose comprises alkylcellulose, hydroxy alkyl cellulose, ether of cellulose, cellulose ester, nitrocellulose, methylcellulose gum, ethyl cellulose, hydroxypropylcellulose, Vltra tears, hydroxy butyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, Cellulose Acetate Phthalate, carboxyethyl cellulose, cellulosetri-acetate, the sulfate cellulose sodium salt, poly-butyric acid, poly-valeric acid and poly-(lactide-be total to-caprolactone).

Natural polymer comprises alginates, and comprises dextran and cellulosic other polysaccharide, collagen, albumin and other hydrophilic albumen, zein and other prolamine and hydrophobin, its multipolymer and mixture.Its chemical derivative used herein refers to replacement, the addition such as the chemical group of alkyl, alkylidene group, hydroxylation, other modification that oxidation and those skilled in the art's routine are carried out.

The biological adhesiveness polymkeric substance comprises H.S.Sawhney, C.P.Pathak and J.A.Hubell are at Macromolecules, 1993,26, bioerodible hydrogel described in the 581-587 also comprises poly-hyaluronic acid, casein, gelatin, glutin, polyanhydride, polyacrylic acid, alginates, chitosan and polyacrylic ester.

Further illustrate,, all can make polymer formation matrix by solvent evaporation, spraying drying, solvent extraction and other method well known by persons skilled in the art.Document description is arranged preparation be applicable to that medicine send the method for the microballoon of passing, for example Mathiowitz and Langer, J.Controlled Release5,13-22 (1987); Mathiowitz, et al., Reactive Polymers6,275-283 (1987); And Mathiowitz, et al., J.Appl. Polymer Sci.35,755-774 (1988).As Mathiowitz, et al., Scanning Microscopy4,329-340 (1990); Mathiowitz, et al., J.Appl.Polymer Sci.45,125-134 (1992); And Benita, et al., J.Pharm.Sci.73,1721-1724 (1984) is described, and selected polymkeric substance, size, formalness, desirable degree of crystallinity are depended in the selection of method.

As Mathiowitz, et al., (1990), and the U.S.Pat.No.4 of Benita and Jaffe, 272,398 is described, and in the solvent evaporation situation, polymkeric substance is dissolved in the volatilizable organic solvent.Be added in this polymers soln with soluble form or particulate form dispersive RNAi construct, contain tensio-active agent just mixture is suspended in, as the aqueous phase of polyvinyl alcohol.Stir the emulsion that obtains,, just stayed microspheres with solid until most of organic solvent volatilization.

Usually, this polymkeric substance can be dissolved in the methylene dichloride.Can adopt some different polymer concentrations, for example, 0.05-0.20g/ml.After adding medicine in this solution, obtaining solution is suspended in 1% (w/v) polyvinyl alcohol that contains of 200mi vigorous stirring, and (Sigma Chemical Co., St.Louis is in distilled water Mo.).Stir after 4 hours, organic solvent volatilizees from polymkeric substance, again with the microballoon that water washing was obtained, and in freeze drier dried overnight.

Obtain relatively stable polymkeric substance by being applicable to,, can obtain the microballoon of different size (the 1-1000 micron is although aerosol applications requires less than 10 microns) and form as the method for polyester and polystyrene.But, unsettled polymkeric substance then may be degraded owing to being exposed to water as polyanhydride.For these polymkeric substance, it may be preferred that heat is melted the method that encapsulates and remove solvent.

Melt in the encapsulation process in heat, polymkeric substance is at first melted, and mixes with the solids of RNAi construct, preferably obtains suitable dimension by screening.This mixture is suspended in not miscible solvent, in silicone oil, and carries out continuously stirring, be heated above the temperature of 5 ℃ of this melting point polymers.In case this emulsion is stable, just its cooling is solidified until this polymer particle.Wash the microballoon that is obtained by the method that adopts the sherwood oil decant, with the mobile meal that gains freedom.Adopt this method can obtain the microballoon that diameter is the 1-1000 micron.Adopt the microballoon outside surface of this technology preparation smooth and fine and close usually.This operation can be used for the water unstable polymkeric substance, but limitation is then arranged when adopting molecular weight to be the polymkeric substance of 1000-50000.

In spray-drying process, polymkeric substance is dissolved in organic solvent, in methylene dichloride (0.04g/ml).The RNAi construct of known quantity suspended (if soluble) or altogether molten (if solvable) in this polymers soln.Then this solution of spraying drying or dispersion system.Adopt this method can obtain the microballoon that diameter is the 1-10 micron, form then depends on selected polymkeric substance.

By the gel type polymkeric substance, the preparation method of the hydrogel microsphere of making as alginates, poly-phosphine piperazine or other dicarboxyl polymkeric substance is as follows, with this polymer dissolution in the aqueous solution, material to be integrated is suspended in this mixture, pushes this mixture of polymers and form device by a kind of droplet that disposes the nitrogen jet device.As Salib, et al., Pharmazeutische Industrie40-111A, 1230 (1978) describe, the microballoon of acquisition falls into the ion hardening bath of slow stirring.As Lim et al., J.Pharm.Sci.70,351-354 (1981) describes, and the advantage of this system is can as the method for polylysine coating, further modify microsphere surface by adopting polycationic polymer after machining.For example, in the situation of alginates,, after machining, make the outside surface and the polycation of particulate then by the ionomer of alginates and calcium ion, crosslinked as polylysine, just can form hydrogel.Adopt extrusion machine, polymkeric substance flow velocity and the gas flow rate of different size, just can control the size of this microsphere particles.

By with polymer dissolution in acidic solution, and can prepare chitosan microball with the crosslinked method of tri-polyphosphate.For example, carboxymethyl cellulose (CMC) microballoon is by making polymer dissolution in acid solution, and adopts the method preparation of lead ion precipitation microballoon and get.Can prepare alginates/polymine (PEI) to reduce the amount of carboxylic group on the alginates microcapsule.

(ii) pharmaceutical composition

This particulate can be suspended in any suitable pharmaceutical carrier, as is used to give patient's salt solution.In most preferred embodiment, preserve particulate with drying or lyophilized form, before administration.Then it can be suspended in the capacity solution, for example be applicable to the aqueous solution with aerosol or dry powder form administration.

The administration of (iii) leading

This particulate can be sent and be passed to specific cells, especially phagocytic cell and organ.As if the phagocytic cell in the aggregate lymphatic nodule can optionally absorb the particulate of oral administration.The phagocytic cell of reticuloendothelial system also can absorb the particulate of intravenously administrable.Can utilize lung's scavenger cell to the engulfing of particulate, make this particulate target decide spleen, marrow, liver and lymphoglandula.

As mentioned above, by adhere to can special XNOR specifically in conjunction with the part of particular target, also can make the particulate guiding.The example of this part also comprises antibody, contains the fragment of variable region, Sugar receptors, hormone or other have the organic molecule of acceptor on the target cell surface.

The (iv) preservation of particulate

In the preferred embodiment, this particulate is that freeze-drying is preserved.Determining of dosage is amount, the rate of release in the pulmonary system and the pharmacokinetics of this compound according to packaged RNAi construct.

(v) sending of particulate passed

Can adopt several different methods to send and pass particulate, scope is advanced nasal meatus so that part particles arrive pulmonary system from direct administration, to utilizing the powder drop instillator, or utilizes the conduit or the pipe of through lung pipeline.Although utilize those devices of hydrocarbon propellants no longer to be utilized, and those devices that depend on the patient respiratory intake can cause dose variations, and commercial available Diskus is still arranged.The example of suitable propelling agent comprises hydrofluoroalkane propellant, as 1,1, and 1,2-Tetrafluoroethane (CF3CH2F) is (HFA-134a) with 1,1,1,2,3,3,3-seven fluoro-n-propanes (CF3CHFCF3) (HFA-227), R 116, monochloro fluoromethane, 1,1-C2H4F2 C2H4F2 and combination thereof.

F. Be used to discharge the medical apparatus coating of RNAi construct

Another aspect of the present invention relates to the cated medical apparatus of coating.For example, in some embodiment, the invention provides the medical apparatus of at least one surface with coating, wherein this coating comprises polymeric matrix of the present invention and RNAi construct.This coating can be applicable to surgical instrument, as screw, plate, packing ring, suture line, prosthese anchoring device, hobnail, bail, electricity lead, valve, film.This device can be conduit, implantable vessel access port, storage blood bag, blood transfusion tube, central vein conduit, ductus arteriosus, blood vessel implant, IABP, heart valve, cardiovascular suture line, artificial heart, pacemaker, heart chamber auxiliary pump, device outside, hemofilter, hemodialysis assembly, hemoperfusion assembly, plasma exchange assembly and be suitable for unfolded filter in the blood vessel.

Some according to embodiment of the present invention in, the monomer that forms polymkeric substance makes up with the RNAi construct, with the two mixing, this RNAi construct is dispersed in the monomer solution.Then according to conventional coating process, this dispersion system is added into support or other device, afterwards by normal starter, as UV light starting cross-linking process.In according to other embodiments of the present invention, polymer composition and the combination of RNAi construct form dispersion system.Then the surface that this dispersion system is used for medical apparatus, the crosslinked solid cladding that just formed takes place in polymkeric substance.In other embodiments according to the present invention, polymkeric substance and RNAi construct and suitable solvent combination form dispersion system, in a usual manner this dispersion system are used for support then.By ordinary method, as thermal evaporation, desolvate just can remove afterwards, polymkeric substance and RNAi construct (common formation continues to discharge medicine and send the system of passing) are then stayed on the support as coating protection.In situation about the RNAi construct being dissolved in the polymer composition, also can use similar approach.

In according to certain embodiments of the present invention, system comprises hard relatively polymkeric substance.In other embodiments, system comprises soft and extensile polymkeric substance.Also have in some embodiments, system comprises the polymkeric substance with adhesion characteristics.The hardness of polymkeric substance, elasticity, viscosity and other characteristic are extensively variable, and as hereinafter more concrete argumentation, these characteristics depend on the specific final form of system.

Embodiment according to system of the present invention has multiple multi-form.In some embodiment, system is made up of the RNAi construct that suspends or be dispersed in the polymkeric substance.In some other embodiment, system is made up of RNAi construct and semisolid or gelatin polymer, can be injected in the body via syringe.In other embodiments according to the present invention, system is made up of RNAi construct and soft flexible polymkeric substance, can be inserted into or implants by suitable surgical method.According to the present invention further in the embodiment, system is made up of hard solid polymer, can be inserted into or implants by suitable surgical method.In further embodiment, system comprises the polymkeric substance that suspends or be dispersed with the RNAi construct, and wherein RNAi construct and polymeric blends have formed coating on such as surgical instruments such as screw, support, pacemakers.In particular according to the present invention, this device is made up of hard solid polymer, is fixed to the form of surgical instrument, as surgical screw, plate, support etc., or certain part of these apparatuses.In other embodiments according to the present invention, system comprises suture form, and disperses or be suspended with the polymkeric substance of RNAi construct.

In according to certain embodiments of the present invention, the medical apparatus that contains matrix is provided, this matrix has a surface, for example outside surface and on coating.This coating contains polymkeric substance, and is dispersed with the RNAi construct in this polymkeric substance, and the RNAi construct is penetrated, and perhaps discharges this RNAi construct after the biological degradation.In according to certain embodiments of the present invention, this device comprises and suspends or be dispersed in RNAi construct in the suitable polymers, and wherein this RNAi construct and polymkeric substance are coated on the whole substrate, as surgical instrument.This coating can realize by spraying or dip-coating mode.

In other embodiments according to the present invention, this device comprises RNAi construct and polymer suspension or dispersion system, and wherein this polymkeric substance is hard, and has formed an integral part of the device that is inserted into or implants.For example, in particular instance according to the present invention, this device is for being coated with the surgical screw that suspends or be dispersed in the RNAi construct in the polymkeric substance, support, pacemaker etc.In other particular according to the present invention, be suspended with the RNAi construct polymer formation the tip or the head of surgical screw, or its part.In other embodiments according to the present invention, suspend or the polymkeric substance that is dispersed with the RNAi construct is coated on such as on the surgical instruments of surgery with pipe (as colostomy, abdominal irrigating catheter and intravenously pipe).According to the present invention further in the embodiment, this device is for being coated with the intravenous needle of polymkeric substance and RNAi construct.

As above discuss, coating according to the present invention comprises biological erodable or abiotic erodible polymkeric substance.The selection of biological erodable and abiotic erodable polymkeric substance is based on the plan end-use of system or device.In according to certain embodiments of the present invention, this polymkeric substance can be by advantageously biological attack.For example, when system is during such as the coating on the surgical implantable device such as screw, support, pacemaker, this polymkeric substance can be by advantageously biological attack.According to the present invention, polymkeric substance can be comprised some device by other embodiment of advantageously biological attack, this device be the RNAi construct in polymkeric substance, form implantable, suck or the suspension or the dispersion system of injection, wherein this device does not utilize other assembly (as screw or deadman).

According to the present invention, polymkeric substance is difficult to penetrate and is difficult in some embodiment of biological attack, the biological attack speed of this polymkeric substance advantageously fully is lower than the rate of release of RNAi construct, therefore still be retained in original position in the long period section of this polymkeric substance after the RNAi construct is released, but final still by biological attack and reuptake in the surrounding tissue.For example, installing to comprising suspension or being dispersed in the sutural situation of biological erodable of the RNAi construct in the biological erodable polymkeric substance, the biological attack speed of this polymkeric substance is advantageously fully low, this RNAi construct is released in about 14 days time about 3 with linear mode, and suture line still retains about 3 week to about June.Allied equipment according to the present invention comprises the surgical staples that contains the suspension or be dispersed in the RNAi construct in the biological erodable polymkeric substance.

In according to other embodiments of the present invention, the biological attack speed of polymkeric substance advantageously is positioned at the same order of magnitude with the rate of release of RNAi construct.For example, contain in system and to suspend or be dispersed in RNAi construct in the polymkeric substance, and this is polymer-coated at surgical instrument, in the situation on orthopedic screw, support, pacemaker or the abiotic erodable suture line, this polymkeric substance advantageously with a certain speed by biological attack, under this rate behavior, the surface-area that directly is exposed to the RNAi construct of body tissue on every side is along with the time keeps constant basically.

In other embodiments according to the present invention, polymer support can be penetrated as the moisture content in the blood plasma by surrounding tissue.In these situations, penetrable this polymkeric substance of the aqueous solution, thus touch the RNAi construct.This dissolution rate may be subjected to a complex set of Variable Control, as perviousness, the solubleness of RNAi construct, pH, the ionic strength of polymkeric substance, and the protein composition of physiologic fluid etc.

In according to certain embodiments of the present invention, polymkeric substance is abiotic erodible.Comprise in system and to await being coated on some surgical instrument, and in the situation of the polymkeric substance of a formation one integral part, wherein these surgical instruments are fit to by for good and all, insert perhaps semipermanently or implant, and then abiotic erodable polymkeric substance is especially effective.The exemplary device that has polymkeric substance to advantageously generate the permanent coating on the surgical instrument comprises orthopedic screw, support, prosthetic joint, artificial valve, permanent suture line, pacemaker etc.

After the coronary angioplasty of Pi Jing chamber, may use multiple different support.Although may use many supports, for simplicity, will be described to the support of limited quantity in the typical embodiments of the present invention according to the present invention.Those skilled in the art will recognize that the many supports relevant with the present invention all may be utilized.In addition, as mentioned above, also may utilize other medical apparatus.

Support is often used as the inboard tubular structure in a catheter lumen left side and blocks symptom with alleviation.Usually, support is inserted in the tube chamber with not expansion form, and then automatically, perhaps trails under the help of second device in position.The realization of typical case's stretching method is to be installed in supravasal angioplasty sacculus by utilization, and this sacculus expands in blood vessel that narrows down or body passageway, can shear and destruction and vessel wall are formed the obstruction that links to each other, thereby obtain the tube chamber of expansion.

Utilize several different methods all can make support of the present invention.For example, can make this support from the stainless steel tube hollow or that be shaped that may utilize laser, electrospark machining, chemical erosion or alternate manner mechanical workout to cross.The support that does not stretch is inserted body, and be placed on the expection site.In a kind of typical embodiments, by foley's tube support is launched in blood vessel, wherein the final diameter of this support changes with the diameter of balls ductus bursae is different.

Should be appreciated that according to support of the present invention and can embody that this shape-memory material comprises, for example nickel and titanium or stainless suitable alloy by shape-memory material.

By the method that stainless steel is shaped in a predefined manner, for example it is twisted into the twisted shape configuration, the configuration that stainless steel can be formed be made from extensibility.In this embodiment, behind the formation support, it can be compressed, so that its occupation space is fully little of being inserted in blood vessel or other tissue by inserted mode, wherein this inserted mode comprises suitable conduit or elastic rod.

When from conduit, deviating from, can make stent forming be stretched to the expection configuration, this stretching, extension be automatically or the change by pressure, temperature or electricity irritation cause.

Regardless of the design of support, preferably contain the support of RNAi construct, wherein this RNAi construct has enough specificitys, and the full concentration that effective dose can be provided in damage zone.In this, " the storage size " in the coating is preferably through estimating, so that the RNAi construct of desired amount fully to be provided at predetermined site.

In the another kind of typical embodiments, whole surfaces externally and internallies of support all can be coated with the RNAi construct of therapeutic dose.But, emphasis is that the change of pointing out this coating technology may be depended on the RNAi construct.Equally, the change of this coating technology also may be depended on the material that comprises medical apparatus in support or other chamber.

Medical apparatus has and continue to discharge medicine and send and pass coating in the chamber.By conventional coating process,, RNAi construct coating can be coated on the support as dip coated, spraying and dip-coating.

In a kind of embodiment, medical apparatus comprises the tubular bracket of the radial stretching, extension of prolongation in the chamber, and this support has an inner cavity surface and an opposed outer surface that stretches along the support longitudinal center line.This support can comprise permanent implantable stent, implantable stent graft or temporary stent, and wherein temporary stent is defined as and can stretches in blood vessel, afterwards the support that can be fetched by blood vessel.Stent configuration can comprise that coiling support, memory disc are around support, Nitinol support, network, pin hand support, bush support, permeable support, the support that contains temperature sensor, porous support etc.According to conventional methods, as by the inflatable ball ductus bursae, by self-deploying mechanism (after conduit discharges),, support is launched perhaps by other suitable mode.The tubular bracket of the radial stretching, extension of this prolongation can be a stent graft, and wherein this stent graft is in graft or an outside set composite with support.This graft can be the blood vessel implant, such as ePTFE graft, biology graft or braiding graft.

There is Several Methods the RNAi construct can be incorporated into or attached on the support.In the typical embodiments, the RNAi construct directly is integrated in the polymeric matrices, and is sprayed on rack outer surface.The RNAi construct discharges from polymeric matrices in time, enters surrounding tissue.The RNAi construct preferably is retained on the support at least 3 days until about 6 months, more preferably 7-30 days.

In some embodiment, polymkeric substance according to the present invention comprises biology tolerance polymkeric substance, and promptly it can make the RNAi construct see through, and the perviousness that it has not is the main speed determinative of RNAi construct rate of release from polymkeric substance.

In according to certain embodiments of the present invention, polymkeric substance is abiotic erodible.That the example of the abiotic erodable polymkeric substance of utilization of the present invention comprises is poly-(ethene is poly--altogether-vinyl-acetic ester) (EVA), polyvinyl alcohol and urethane, as the urethane based on polycarbonate.In other embodiments of the present invention, polymkeric substance is biological erodible.The example of the biological erodable polymkeric substance of utilization of the present invention comprises polyanhydride, poly(lactic acid), polyglycolic acid, poe, polyalkyl alpha-cyanacrylate or derivatives thereof and multipolymer.As more specifically described below, experienced technician will be appreciated that the final physical form that the biological attack of polymkeric substance or abiotic rodent selection is depended on system.Other typical polymers includes organosilicon polymer and hyaluronic acid derived polymers.It is to get being fit to give under the infiltrative condition preparation that experienced technician should understand polymkeric substance according to the present invention, so it is not the main speed determinative that the RNAi construct discharges from polymkeric substance.

In addition, suitable polymers comprises and body fluid and mammalian tissues bio-compatible, and is insoluble to natural existence the (collagen, hyaluronic acid etc.) or the synthetic material of the body fluid of contact with it basically.In addition, suitable polymers can stop the interaction between protein is formed in the RNAi construct that disperses/be suspended in this polymkeric substance and the body fluid basically.In some situation, in view of polymkeric substance may dissolve, perhaps with can influence the constant protein of drug release and form and interact, therefore should avoid adopting rapidly-soluble polymkeric substance, highly dissolve in body fluid or allow that RNAi construct and protein forms interactional polymkeric substance.

Other suitable polymers comprises polypropylene, polyester, polyethylene vinylacetate (PVA or EVA), polyethylene oxide (PEO), poly(propylene oxide), poly carboxylic acid, polyalkyl acrylate, ether of cellulose, silicone, poly-(dl-lactide-co-glycolide), multiple Eudragrit (NE30D for example, RS PO and RL PO), poly-alkyl-alkyl acrylate copolymer, the polyester-polyurethane ester block copolymer, polyethers-block polymers of polyurethane, poly-P-Dioxane ketone, poly beta-hydroxybutyrate, poly(lactic acid) (PLA), pla-pcl, polyglycolic acid and PEO-PLA multipolymer.

Forming coating of the present invention can carry out by the following method, is about to one or more suitable monomers and mixes with suitable R NAi construct, makes monomer polymerization form polymeric system then.By this mode, the RNAi construct is just dissolved or be dispersed in the polymkeric substance.In other embodiments, the RNAi construct is mixed in liquid polymers or the polymer dispersed system, further processes this polymkeric substance then to form coating of the present invention.That other suitable procedure of processing can comprise is crosslinked with suitable crosslinked RNAi construct, the further polymerization of liquid polymers or polymer dispersed system, with the suitable monomers copolymerization, with the block copolymerization of suitable polymers piece etc.Further procedure of processing is sunk in the polymkeric substance RNAi construct, thereby this RNAi construct is suspended or is dispersed in the polymer support.

Many non-erodible polymkeric substance all can combine application with the RNAi construct.The film-forming polymer that can be used to the application's floating coat can be can absorb or non-absorbable, and must be biocompatible, to minimize the stimulation to vessel wall.This polymkeric substance can be a Biostatic or biological absorbable, the expection rate of release or the expection extent of stability that depend on polymkeric substance, but biologically absorbable polymer may be preferred, because different with Biostatic polymer, biologically absorbable polymer can be after implantation long-term existence and cause any harmful, chronic local reaction.In addition, there is not risk as described below in biologically absorbable polymer, promptly since may repel coating and even still may be introduced the bioenvironmental pressure of a further difficult problem after enclosing tissue at support, cause adhering between support and the coating to be lost along with the prolongation of time.

Adoptable suitable film forming biologically absorbable polymer comprises the polymkeric substance that is selected from aliphatic polyester, polyamino acid, copolymerization ether-ester, poly-oxalic acid alkylene ester, polymeric amide, poly-iminocarbonic ester, poe, polyoxaester, polyamidoamines ester, the polyoxaester that contains amido group, polyanhydride, polyphosphonitrile, biomolecules and composition thereof.For the object of the invention, aliphatic polyester comprises that the homopolymer of lactide and multipolymer (comprise lactic acid d-, l-and meso lactide), 6-caprolactone, glycollide (comprising oxyacetic acid), butyric ester, hydroxyl valerate, P-Dioxane ketone, Texacar PC (and alkyl derivative), 1,4-dioxepan-2-ketone, 1,5-dioxepan-2-ketone, 6,6-dimethyl-1,4-diox-2-ketone and polymeric blends thereof.For the purpose of the present invention, poly-iminocarbonic ester comprises Kemnitzer and Kohn at Domb, the Handbook of Biodegradable Polymers that Kost and Wisemen edit, Hardwood Academic Press, 1997, the described polymkeric substance of 251-272 page or leaf.For the purpose of the present invention, the copolymerization ether-ester comprises that Cohn and Younes is at Journal ofBiomaterials Research, Vol.22, the 993-1009 page or leaf, 1988, and Cohn is at Polymer Preprints (ACS Division of Polymer Chmistry) Vol.30 (1), 498 pages, the described copolymerization ether-ester of 1989 (as PEO/PLA).For the purpose of the present invention, gather the oxalic acid alkylene ester and comprise United States Patent(USP) Nos. 4,208,511; 4,141,087; 4,130,639; 4,140,678; 4,105,034; With 4,205, those that describe in 399 (being hereby incorporated by).As Allcock at The Encyclopedia of Polymer Science, Vol.13,31-41 page or leaf, Wiley Intersciences, John Wiley﹠amp; Sons, 1988 and Vandorpe, Schacht, Dejardin and Lemmouchi are at Domb, the Handbook of Biodegradable Polymers that Kost and Wisemen edit, HardwoodAcademic Press, 1997,161-182 page or leaf (being hereby incorporated by) is described by L-rac-Lactide, D, the polyphosphonitrile that L-rac-Lactide, lactic acid, glycollide, oxyacetic acid, P-Dioxane ketone, Texacar PC and 6-caprolactone are made, altogether-, ternary-with based on higher progression blended polymer of monomers.By the polyanhydride that the diacid of HOOC-C6H4-O-(CH2) m-O-C6H4-COOH form forms, wherein m is an integer among the 2-8, and the multipolymer that forms with aliphatic alpha-ω diacid until 12 carbon.In United States Patent(USP) Nos. 5,464,929; 5,595,751; 5,597,579; 5,607,687; 5,618,552; 5,620,698; 5,645,850; 5,648,088; Polyoxaester polyoxaamides and the polyoxaester that contains amine and/or amide group have all been described in the one or more patents in 5,698,213 and 5,700,583 (being hereby incorporated by).Poe such as Heller be at Domb, the Handbook of Biodegradable Polymers that Kost and Wisemen edit, and Hardwood AcademicPress, 1997,99-118 page or leaf (being hereby incorporated by) is described.For the purpose of the present invention, the film-forming polymer biomolecules comprises can be by enzyme liberating in human body, the perhaps naturally occurring material of hydrolytically unstable in human body, as scleroproein, Fibrinogen, collagen, elastin, and absorbable physiologically acceptable polysaccharide, as chitosan, starch, lipid acid (and ester class), glucose glycan and hyaluronic acid.

Suitable film forming Biostatic polymer with low relatively chronic tissue's reaction, as urethane, silicone, poly-(first) acrylate, polyester, polyalkylene oxide (polyethylene oxide), polyvinyl alcohol, polyoxyethylene glycol and Polyvinylpyrolidone (PVP), and those also can be used such as the hydrogel that is formed by crosslinked Polyvinylpyrolidone (PVP) and polyester.It also can adopt other polymkeric substance, as long as can dissolve, solidifies or be aggregated on the support.These polymkeric substance comprise polyolefine, polyisobutene and ethylene-alpha-olefin copolymer; Acrylate copolymer (comprising methacrylic ester) and multipolymer, vinyl halide polymkeric substance and multipolymer are as polyvinyl chloride; Polyvingl ether is as polyvinyl methyl ether; Poly-vinylidene halide is as poly(vinylidene fluoride) and polyvinylidene dichloride; Polyacrylonitrile, polyvinyl ketone; Polyethylene aromatic hydrocarbon is as polystyrene; Polyvinyl ester is as polyvinyl acetate; Vinyl monomer each other with the formed multipolymer of alkene, as ethylene-methyl methacrylate methyl terpolymer, acrylonitritrile-styrene resin, ABS resin and vinyl-vinyl acetate copolymer; Polymeric amide is as nylon 66 and polycaprolactam; Synolac; Polycarbonate; Polyoxymethylene; Polyimide; Polyethers; Resins, epoxy, urethane; Regenerated fiber; Regenerated fiber-triacetate, Mierocrystalline cellulose, rhodia, cellulose acetate butyrate; Cellulose film; Nitrocellulose; Cellulose propionate; Ether of cellulose (being carboxymethyl cellulose and hydroxy alkyl cellulose); And combination.For the application, polymeric amide also comprises-NH-(CH ₂) _n-CO-and NH-(CH ₂) _x-NH-CO-(CH ₂) _yThe polymeric amide of-CO form, wherein a n integer among the 6-13 preferably; X is an integer among the 6-12; Y is an integer among the 4-16.More than listed polymkeric substance only for for example, the present invention is not construed as limiting.

The polymkeric substance that is used as coating can be that molecular weight is enough high and can waxization or the film-forming polymer that is clamminess.This polymkeric substance also should be attached on the support, and after being deposited on the support, should be not yielding and be removed under hemodynamic pressure.This polymericular weight should be enough to provide sufficient toughness, thereby in the conveying of support or between extensin period, this polymkeric substance is not rubbed off, and does not break between extensin period at support.In some embodiment, the melt temperature of this polymkeric substance is more than 40 ℃, and is preferred about more than 45 ℃, more preferred more than 50 ℃, highly preferred more than 55 ℃.

Just can make coating by one or more therapeutic RNAi construct is mixed the formation coating mix with coated polymeric.The existence form of RNAi construct can be liquid, subdivided solids, or other any suitable physical form.This mixture can comprise one or more additives arbitrarily, as nontoxic complementary material, such as thinner, carrier, vehicle, stablizer etc.Other suitable additive can be prepared together with polymkeric substance and RNAi construct.For example, the hydrophilic polymer that is selected from the above listed physiologically acceptable film-forming polymer can be added in the physiologically acceptable hydrophobic coating, to improve release characteristics (maybe hydrophobic polymer can be added in the hydrophilic coating) to improve release characteristics.An example is that the hydrophilic polymer that will be selected from polyethylene oxide, polyvinylpyrrolidone, polyoxyethylene glycol, carboxymethyl cellulose, Walocel MT 20.000PV and combination thereof is added in the aliphatic polyester coating, with the improvement release characteristics.Suitable relative quantity can be determined by release characteristics in the external and/or body of monitor therapy RNAi construct.

Coat-thickness can determine the speed that the RNAi construct discharges from matrix.Basically, the RNAi construct is to discharge from matrix by the mode via the polymeric matrix diffusion.Polymkeric substance is permeable, thereby allows solid, liquids and gases from wherein discharging.The total thickness of polymeric matrix is between about 1 micron to about 20 microns, and is perhaps wider.Be important to note that can with polymeric matrices attached to medical apparatus on before, utilize primer layer and metal finishing, for example, pickling, alkali cleaning, salinization and poly-para xylylene deposition all can be used as the part in the described all processes.

Further for example proof has many modes will gather that (ethene-altogether-vinyl acetate), poly-n-butyl methacrylate and RNAi construct solution mix in the support or outer.For example, can with this solution spraying on support, perhaps support be immersed in this solution.Other method comprises spin coating and RF plasma polymerization.In a kind of typical embodiments, this solution is sprayed on the support, makes its drying then.In the another kind of typical embodiments, can be with this solution energising and polarity in addition, and support is energized in addition another opposite polarity.In this mode, solution and support will attract each other.In adopting such spraying method, can reduce loss, and can realize coat-thickness is controlled more accurately.

In another typical embodiments, the RNAi construct can be impregnated in the poly-fluo-copolymer of film forming, this multipolymer contains a certain amount of first part that is selected from polymeric vinylidene fluorine and polymeric tetrafluoroethylene, with a certain amount of second part that is different from first part, after second part and first part copolymerization, can produce poly-fluo-copolymer, second part can provide the toughness or the elastic performance of this poly-fluo-copolymer, wherein the relative quantity of first part and second part can effectively be given this coating and its some characteristic of film that is produced, and these characteristics can be applied in effectively in the process of handling implantable medical apparatus.

In a kind of embodiment according to the present invention, in the medical apparatus, the outside surface of extensible tubular bracket comprises according to coating of the present invention in the chamber of the present invention.Rack outer surface with coating is the contact tissue surface, and is biocompatible." continue to discharge the RNAi construct and send the surface of passing the system coating " and " surface of coating " synonym, wherein surface coated, covering or the with good grounds lasting release RNAi construct of the present invention that infiltrates send the system of passing.

In a kind of optional embodiment, in the medical apparatus, the inner cavity surface of the rapid extensible tubular bracket of prolongation or whole surface (promptly interior and outside surface) all has the surface of coating in the chamber of the present invention.Contain the present invention and continue to discharge the RNAi construct to send the inner cavity surface of the system of passing also be the surface of contacting with fluid, and be physiologically acceptable and blood compatibility.

V. Typically used

In one aspect, the inventive method is used to suppress, or reduces undesirable cell growth in the body, the especially growth of transformant at least.In some embodiment, the inventive method is utilized RNAi optionally to suppress coding propagation and is regulated proteic genetic expression.For example, can adopt the inventive method to suppress the expression of some gene product, this gene product is to the mitotic division of target cell and or stop the target cell apoptosis to be absolutely necessary.It is corresponding that RNAi construct of the present invention can be designed to regulate with the fixed propagation of the target of encoding encoding sequence or the other parts of proteic mRNA.When adopting this RNAi construct to handle, the expression forfeiture phenotype that occurs in the target cell will cause this cell to be in dormancy or beginning apoptosis.

In some embodiment, but select RNAi construct of the present invention to suppress the expression of stimulate cell growth and mitotic gene product.Can be those known oncogene by the fixed gene kind of the inventive method target.Term used herein " oncogene " refers to the gene of stimulate cell growth, and when its when this intracellular expression level reduces, cell growth rate just reduces or this cell begins dormancy.In the context of the present invention, oncogene comprises intracellular protein, and may be by the extracellular somatomedin of autocrine or the cell proliferation of paracrine functional stimulus.The RNAi construct can be designed at human oncogene example comprise c-myc, c-myb, mdm2, PKA-I (I type protein kinase A), Abl-1, Bcl2, Ras, c-Raf kinases, CDC25 Phosphoric acid esterase, cyclin, cell cycle protein dependent kinase (cdks), Telomerase, PDGF/sis, erb-B, fos, jun, mos, src, abovely only enumerated a few.In the context of the present invention, oncogene also comprises the fusion gene that chromosome translocation causes, and for example, Bcr/Abl merges oncogene.

In some preferred embodiment, be according to suppressing transformant, especially the ability of the requisite genetic expression of propagation of tumour cell is selected RNAi construct of the present invention.Can adopt this RNAi construct as at superfluous that give birth to, undifferentiated and/or the treatment of hyperplasia sexual cell growth or the part of prevention in the body, comprise a part as oncotherapy.C-myc protein is not regulated in the cancer of various ways, and causing expressing increases.The reduction of external c-myc rna level is with apoptosis-induced.Therefore the siRNA that is complementary to c-myc may be able to be used as the therapeutical agent of anticancer disease treatment.Preferably, RNAi construct of the present invention can be applied in the treatment of lymphocytic leukemia.Normally the Bcr/Abl fusion product causes lymphocytic leukemia because karyomit(e) 9 and 12 transpositions produce.The fusion rotein that is obtained is used as oncogene; Therefore, the specificity eliminating to the Bcr/Abl fusion mRNA just may cause leukemia cell's death.In fact, the siRNA molecule transfection that is specific to the Bcr/Abl fusion mRNA is advanced among the leukemia cell of cultivation, not only can reduce fusion mRNA and corresponding oncoprotein, can also induce the apoptosis of these cells (to see Wilda et al. for example, Oncogene, 2002,21:5716-5724).

In other embodiments, be according to suppressing lymphocytic activation, as the propagation of B cell or T cell, especially the ability of the requisite genetic expression of lymphocyte activation of antigen mediation is selected RNAi construct of the present invention.Can adopt this RNAi construct to press down prescription, as the part of conduct to the treatment or the prevention of immune-mediated inflammatory diseases as immunity.

In some embodiment, can use method treatment autoimmune disease described herein.For example, select RNAi construct of the present invention according to the ability of the genetic expression that suppresses coding or adjusting cytokine-expressing.Correspondingly, can adopt to cause cytokine, as the construct of the expression by inhibitation system of THF α, IL-1 α, IL-6 or IL-12 or its combination or minimizing a part as treatment or prevention rheumatoid arthritis.Similarly, the construct that causes the related cytokine-expressing of inflammation to be suppressed or to reduce can be applied in inflammation and inflammation related disease, in the treatment or prevention as multiple sclerosis.

In other embodiments, according to suppress the diabetes outbreak or carry out involve genetic expression ability select RNAi construct of the present invention.For example, artificial diabetes is found and expresses with loose related p21WAF1/CIP1 (p21) of renal glomerulus and TGF-β 1 that increase is relevant (sees for example Al-Douahji, et al. Kidney Int.56:1691-1699).Correspondingly, the construct that causes these protein expressions to be suppressed or to reduce can be applied in treatment of diabetes or the prevention.

In other embodiments, select RNAi construct of the present invention according to the ability that suppresses ICAM-1 (intracellular adhesion molecule) expression.Suppressing the antisense nucleic acid of ICAM-1 expression is researched and developed at psoriasis by Isispharmaceutics company.In addition, being considered at the antisense nucleic acid of ICAM-1 gene can prophylaxis of acute renal failure and reperfusion injury, and prolongs the isograft survival time of kidney and (for example see Haller et al. (1996) Kidney Int.50:473-80; Dragun et al. (1998) Kidney Int.54:590-602; Dragun et al. (1998) Kidney Int.54:2113-22).Correspondingly, the present invention has considered the purposes of RNAi construct in above-mentioned disease.

In other embodiments, according to other cell proliferation that suppresses smooth muscle cell or blood vessel endothelium, the ability that forms the requisite genetic expression of proliferative cell that relates to such as neointima is selected RNAi construct of the present invention.In these embodiments, the inventive method can be used as the part of treatment or prevention of restenosis.

Only illustrate, the RNAi construct that is applied to vascular endothelial cell in postangioplasty can reduce the propagation of these cells after operation.Only illustrate, particular instance is the siRNA that is complementary to c-myc (a kind of oncogene).The downward modulation of c-myc has suppressed the cell growth.Therefore, can prepare siRNA by synthetic following oligonucleotide:

5′-UCCCGCGACGAUGCCCCUCATT-3′

3′-TTAGGGCGCUGCUACGGGGAGU-5′

Except the thymus nucleic acid that runic shows, promptly beyond the thymidine, all bases are Yeast Nucleic Acid (for higher stability).Be blended in the solution that contains 10mM Tris-Cl (pH7.0) and 20mM NaCl by the oligonucleotide that will wait volumetric molar concentration, be heated to 95 ℃ after, slowly cool to 37 ℃ then, just can obtain double-stranded RNA.Then can siRNA that purifying obtains by agarose gel electrophoresis, and with its send pass to free or with send the system of passing, such as polymkeric substance compound cell based on cyclodextrin.For experiment in vitro, by growth curve analysis, RT-PCR or can monitor the effect of siRNA to the proteinic western blot analysis of c-myc.

Confirmed directly antisense oligodeoxyribonucleotide,, can suppress restenosis and (see for example Kutryk et al. (2002) when quilt in crown structural transplantation after send when passing the part immediately at the c-myc gene J Am Coll Cardiol.39:281-287; Kipshidze et al. (2002) J Am Coll Cardiol.39:1686-1691).Therefore, the present inventor consider will at the RNAi construct (being c-Myc RNAi construct) of c-Myc gene together with penetrant send the system of passing to send to pass to the structural transplantation site (Interventional Technologies, San Diego, California).Preferably, this c-Myc RNAi construct directly is coated on the support, to suppress restenosis.Similarly, can the part send and pass c-Myc RNAi construct, to suppress forming the endomysium hyperplasia that art (PTCA) occurs afterwards through Pi Jing chamber coronary vasodilator, this part send the typical method of passing at for example Kipshidze et al. (2001) Catheter Cardiovasc Interv.Describe to some extent among the 54:247-56.Preferably, adopt for example thiophosphatephosphorothioate or phosphoramidate chemically modified RNAi construct.

Early growth response factor-1 (being Egr-1) is to be activated during mechanical injuries, and regulates cell proliferation and the transcription factor of moving related many gene transcription.Therefore, this proteinic downward modulation also may be the approach of prevention of restenosis.Can prepare siRNA by synthetic following oligonucleotide at Egr-1:

5′-UCGUCCAGGAUGGCCGCGGTT-3′

3′-TTAGCAGGUCCUACCGGCGCC-5′

Equally, except the thymus nucleic acid that runic shows, promptly beyond the thymidine, all bases are Yeast Nucleic Acid.Just can prepare siRNA from these oligonucleotide, and as mentioned above with in its transfered cell.

Embodiment

Above described the present invention prevailingly, just can more easily understand the present invention with reference to following embodiment, it is illustration some aspect of the present invention and embodiment only that these embodiment are included, and the present invention is not construed as limiting.

1. External the sending of the plasmid DNA of coding siRNA passed

Human embryos nephrocyte (HEK 293-EcR) is advanced in 6 well culture plates with 200,000 cell inoculations in every hole.These HEK 293-EcR cells by the coding ecdysone receptor the plasmid stable transfection.After 2-3 days, adopt the common transfectional cell of pIND-rev-GFP (a kind of coding can be induced the plasmid of element and egfp) and pTZU6+1/siRNA (a kind of plasmid that justice and antisense strand are arranged of the siRNA of coding oligonucleotide).In 0.5ml opti-MEM, this plasmid (is seen Lee et al. (2002) with the ratio of 15N/P Nature Biotechnology, 20:500-505) compound with side chain PEI25k-hi-CD polymkeric substance (high cyclodextrin graft(ing) degree).After 4 hours, replace this substratum with the 2ml perfect medium.The 24th hour,, express to induce the GFP target cell by 5 μ M ponasterone A inducing cells.The 72nd hour, by the versene emigrated cells, with its collection, and by its GFP expression of flow cytometry analysis.As shown in Figure 1, the transfection of siRNA is reduced the GFP expression in dosage dependence mode.When adopting 2 microgram siRNA, observe GFP and express to descend approximately 50%, and when adopting 4 microgram siRNA, then observe GFP and express decline about 40%.Above-mentioned experiment confirm can successfully send the RNAi construct in the culturing cell that goes forward one by one by means of the beta-cyclodextrin polymkeric substance, and expresses by RNA interference mechanism reducer.

2. External DNA plasmid send to be passed and luciferase expression

The BHK-21 cell inoculation is advanced in 24 well culture plates, and under serum-free condition, adopt with multiple different proportionings and 1 μ g pGL3-CV plasmid (a kind of plasmid that the contains luciferase gene) transfection of beta-cyclodextrin polymkeric substance (β CDPs) compound.By to the active calibrating of luciferase protein matter determining transfection efficiency, the result is with relative light unit (RLUs) expression (see figure 2).Weigh cell viability with the protein mass that was obtained in the cell lysates in 48 hours after the transfection.(Hercules CA) determines the protein level of transfectional cell, and adopts the protein level by the cell of naked DNA transfection to carry out stdn to pass through Biorad ' s DC analysis of protein.Different concns according to the ox IgG (Biorad) in the cell cultures lysis buffer is marked and drawn the protein typical curve.Above-mentioned experiment confirm can be optimized transfection efficiency by the proportioning of regulating between beta-cyclodextrin polymkeric substance and the RNAi construct.

3. The intravital DNA plasmid of mouse send to be passed and luciferase expression

Except DNA is by 0.2 μ m filter filtration sterilization, and before using beyond the freeze-drying, other material is constant.Preparation linear cyclodextrin polymkeric substance in 10% glucose, and it is added in the water that equal-volume contains pGL3-CV plasmid (a kind of plasmid that contains luciferase gene), making final solution is 5% glucose solution.Preparation 5+/-particle, and final DNA concentration is 0.5mg/mL.The polymers soln that adopts 200 μ L to contain 100 μ g fluorescein enzyme dnas advances in the female Balb/C mouse body via introportal infusion.After the DNA administration 4 hours, anesthetized mice is injected into its peritonaeum inner chamber with fluorescein, and utilizes the Xenogen camera imaging to obtain luciferase protein matter activity.In 4 hours, in liver, observe luciferase expression after the plasmid administration.Above-mentioned experiment confirm and beta-cyclodextrin polymkeric substance compound RNAi construct can be sent (in the mouse body) in the body that goes forward one by one.

4. External the sending of siRNA oligonucleotide passed

Human acute leukemia K562 suspension cell (the endogenous expression with p210Bcr-Abl fusions) is advanced in 6 well culture plates that every hole contains 0.5ml opti-MEM with 1,000,000 cell inoculation in every hole.Polymer is to adopt 2 μ M dsRNA among the 0.25ml opti-MEM (DharmaconResearch Inc.) with the also linear PEI-hi-CD polymkeric substance in 0.25ml opti-MEM, forms with the ratio of 15N/P.Following dsRNA oligonucleotide is designed to discern Bcr-Abl syzygy mRNA montage thing 1 target:

5′-GCAGAGUUCAAAAGCCCUUdTdT-3′

3′-dTdTCGUCUCAAGUUUUCGGGAA-5′

The 0.5ml transfection media is added in the 0.5ml cell.After 4 hours, every hole replenishes the 4ml perfect medium.The 48th hour, collecting cell, washing, and cracking.Measure protein concn, and with sample on the 20 μ g protein to the SDS-PAGE gel, the beginning electrophoresis.Protein transduction is moved on the pvdf membrane, by the 1%BSA sealing, and by anti-Bcr antibody trace.Detect the p210 signal by chemoluminescence (Amersham), and by comparing with unprocessed sample, the reduction of band intensity is with the observation downward modulation.Above-mentioned experiment confirm is formulated in the gene therapy that siRNA in the supramolecular complex (as the beta-cyclodextrin polymkeric substance) could be passed and be used for acute leukemia by sending.

5. The intravital DNA enzyme of mouse send to be passed

The particle that adopts 250 μ L to contain the D5W preparation of 1mg fluorescent label DNA enzyme is injected into carries in the knurl nude mouse.Prescription contains as mentioned above CD polymkeric substance, AD-PEG and the AD-PEG-Transferrins,iron complexes (be used for target and decide tumour) of [Bellocq, 2002#459].Inject and put to death mouse in back 24 hours, and the tumour of being extracted by the fluorescent and stereo microscopical analysis.DNA enzyme location is by the confocal microscope visual inspection in the cell.Crossing the tumour hat and entering penetrating in the tumour cell is just to realize by means of the particle that Transferrins,iron complexes is modified.Above-mentioned experiment confirm beta-cyclodextrin polymkeric substance can be used to send in the body passs other expression construct (as the DNA enzyme), to carry out gene therapy.

6. The intravital long RNA of mouse send and passs

Except RNA is by 0.2 μ m filter filtration sterilization, and before using beyond the freeze-drying, other material is constant.Preparation linear cyclodextrin polymkeric substance in 10% glucose, and it is added in the water that equal-volume contains the fluorescein ribozyme, making final solution is 5% glucose solution.Preparation 5+/-particle, and final RNA concentration is 0.5mg/mL.The polymers soln that 200 μ L is contained 100 μ g fluorescein ribozymes advances in the female Balb/C mouse body via introportal infusion.After the RNA administration 4 hours, anesthetized mice is injected into its peritonaeum inner chamber with fluorescein, and utilizes the Xenogen camera imaging to obtain luciferase protein matter activity.In 4 hours, in liver, observe luciferase expression after the administration of fluorescein ribozyme.Above-mentioned experiment confirm and the long RNA of beta-cyclodextrin polymkeric substance compound can be sent (in the mouse body) in the body that goes forward one by one.

Claims

1. stable breathing prescription that comprises the RNAi construct, this RNAi construct be configured to be used for will the treatment significant quantity the RNAi construct send by lung or nose and pass lung to the patient.

2. the prescription of claim 1, wherein the RNAi construct is configured to mean diameter less than 20 microns particulate.

3. the prescription of claim 2, wherein the mean diameter of particulate is the 0.5-10 micron.

4. the prescription of claim 2, wherein particulate is formed by biodegradable polymer.

5. the prescription of claim 2, wherein particulate is by one or more polymer formation in the polymkeric substance that is selected from polysaccharide, diketopiperazine, poly-hydroxy acid, polyanhydride, polyester, polymeric amide, polycarbonate, poly-alkylene, polyvinyl compound, polysiloxane, vinylformic acid and methacrylic acid, urethane, Mierocrystalline cellulose, poly-butyric acid, poly-valeric acid, poly-(lactide-altogether-caprolactone) or its multipolymer.

6. the prescription of claim 2, wherein particulate is to form by the method that solvent evaporation, spraying drying, solvent extraction or heat are melted encapsulation.

7. the prescription of claim 2, wherein particulate is drying or lyophilized form.

8. claim 1 or 2 prescription, wherein the RNAi construct is configured to the supramolecular complex that comprises the multidimensional derivatized polymers.

9. the prescription of claim 8, wherein supramolecular complex is formed by cationic polymers.

10. the prescription of claim 9, wherein cationic polymers is selected from poly-(L) Methionin (PLL), polyaziridine (PEI), contains the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

11. the prescription of claim 8, wherein supramolecular complex is by the polymer formation of cyclo-dextrin-modified.

12. the prescription of claim 11, wherein supramolecular complex is formed by the polyaziridine of cyclo-dextrin-modified, and has the structure of following formula:

Wherein

And

13. the prescription of claim 1 or 2, wherein the RNAi construct is formulated in the liposome.

14. the prescription of claim 1 comprises propelling agent.

15. the prescription of claim 1 is accommodated in metered dose inhaler, Diskus or the jet-propelled spraying gun.

16. the prescription of claim 1, wherein the amount of preparation of RNAi construct provides the treatment significant quantity with 1-10 dosing.

17. the prescription of claim 1, wherein the RNAi construct comprises the modification to phosphoric acid-sugar backbone or nucleosides.

18. the prescription of claim 17, wherein the RNAi construct comprises the backbone modifications that is selected from thiophosphatephosphorothioate, phosphoramidate, phosphorodithioate, chimeric methyl-phosphonate-phosphodiester, peptide nucleic acid(PNA) and contains the oligomer of 5-proyl-pyrimidine.

19. a dosing aerosol dispenser contains and is useful on lung or nose send the aerosol pharmaceutical compositions of passing, comprise the prescription breathed of RNAi construct.

20. method that realizes the whole body administration of RNAi construct, this method comprises by the pulmonary administration mode, give the patient with the prescription breathed of RNAi construct, wherein the amount that absorbed by dark lung of this RNAi construct can realize that sending of this RNAi construct body dose pass.

21. a prescription that comprises claim 1, and the pharmaceutical preparation of pharmaceutical acceptable carrier.

22. the pharmaceutical preparation of claim 21, wherein pharmaceutical acceptable carrier is selected from pharmaceutically acceptable salt, ester, and the salt of these esters.

23. a pharmaceutical preparation that comprises claim 21, and instruct the drug packages that said preparation is given the specification sheets (literal and/or diagram) of human patients.

24. a composition comprises one or more and is formulated in the supramolecular complex, and amount of preparation is enough to weaken by the RNA interference mechanism RNAi construct of the target gene expression in the cell of handling.

25. the composition of claim 24, wherein the RNAi construct is little RNA interfering (siRNA).

26. the composition of claim 25, wherein the length of siRNA is 19-30 base pair.

27. the composition of claim 24, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

28. the composition of claim 24, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

29. the composition of claim 24 is used to handle cells in vivo.

30. the composition of claim 24 is used to handle cell in vitro.

31. any one composition among the claim 24-28, wherein supramolecular complex is the multidimensional derivatized polymers that comprises linear polymer.

32. any one composition among the claim 24-28, wherein supramolecular complex is the multidimensional derivatized polymers that comprises branched chain polymer.

33. the composition of claim 24, wherein supramolecular complex is formed by cationic polymers.

34. the composition of claim 33, wherein cationic polymers is selected from poly-(L) Methionin (PLL), polyaziridine (PEI), contains the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

35. the composition of claim 24, wherein supramolecular complex is by the polymer formation of cyclo-dextrin-modified.

36. the composition of claim 35, wherein supramolecular complex is formed by the polyaziridine of cyclo-dextrin-modified, and has the structure of following formula:

Wherein

And

37. any one composition among the claim 24-36, assembling for mean diameter is the particle of 20-500nm.

38. the composition of claim 37, wherein the mean diameter of particle is 20-200nm.

39. method that weakens the cells in vivo expression of target gene, this method comprises the RNAi construct that is formulated in the supramolecular complex, dosage is enough to weaken target gene expression by the RNA interference mechanism, thereby changes growth, survival or the differentiation of the cell of handling.

40. the method for claim 39, wherein the RNAi construct is little RNA interfering (siRNA).

41. the method for claim 40, wherein the length of siRNA is 19-30 base pair.

42. the method for claim 39, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

43. the method for claim 39, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

44. the method for claim 39 is used to handle cells in vivo.

45. the method for claim 39 is used to handle cell in vitro.

46. any one method among the claim 39-43, wherein supramolecular complex is the multidimensional derivatized polymers that comprises linear polymer.

47. any one method among the claim 39-43, wherein supramolecular complex is the multidimensional derivatized polymers that comprises branched chain polymer.

48. the method for claim 39, wherein supramolecular complex is formed by cationic polymers.

49. the method for claim 48, wherein cationic polymers is selected from poly-(L) Methionin (PLL), polyaziridine (PEI), contains the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

50. the method for claim 39, wherein supramolecular complex is by the polymer formation of cyclo-dextrin-modified.

51. the method for claim 50, wherein supramolecular complex is formed by the polyaziridine of cyclo-dextrin-modified, and has the structure of following formula:

Wherein

For every kind of situation, R independently represent H, low alkyl group, cyclodextrin part or And

52. any one method among the claim 39-51, wherein supramolecular complex assemble for mean diameter be the particle of 0.5-200 micron.

53. the method for claim 52, wherein the mean diameter of particle is the 0.5-10 micron.

54. a composition that comprises claim 39-43, and the pharmaceutical preparation of pharmaceutical acceptable carrier.

55. the pharmaceutical preparation of claim 54, wherein pharmaceutical acceptable carrier comprise or the salt of multiple acceptable salt, ester and these esters in one or more.

56. a pharmaceutical preparation that comprises claim 54, and instruct the drug packages that said preparation is given the specification sheets (literal and/or diagram) of human patients.

57. coating that is applied to medical device surface, this coating comprises the polymeric matrix that inside is dispersed with the RNAi construct, when the intravital site of implanted patient, the RNAi construct discharges in matrix, and changes growth, survival or the differentiation of near the cell of implanting of device.

58. the coating of claim 57, wherein medical apparatus be selected from that screw, plate, packing ring, suture line, prosthese anchoring device, hobnail, bail, electricity lead, valve, film, conduit, implantable vessel access port, storage blood bag, blood transfusion tube, central vein conduit, ductus arteriosus, blood vessel implant, IABP, heart valve, cardiovascular suture line, artificial heart, pacemaker, heart chamber auxiliary pump, device outside, hemofilter, hemodialysis assembly, hemoperfusion assembly, plasma exchange assembly and be suitable for unfolded filter in the blood vessel.

59. the coating of claim 57, wherein medical apparatus is a support.

60. the coating of claim 60, wherein the RNAi construct is little RNA interfering (siRNA).

61. the coating of claim 60, wherein siRNA length is 19-30 base pair.

62. the coating of claim 57, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

63. the coating of claim 57, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

64. the coating of claim 57, wherein the RNAi construct weakens and is selected from least a target gene expression in cell cycle protein dependent kinase, c-myb, c-myc, proliferating cell nuclear antigen (PCNA), transforming growth factor-beta (TGF-β), transcription factor nf κ B (NF-κ B), E2F, HER-2/neu, PKA, TGF-α, EGFR, TGF-β, IGFIR, P12, MDM2, BRCA, Bcl-2, VEGF, MDR, ferritin, TfR, IRE, C-fos, HSP27, C-raf and the metallothionein gene.

65. a method that adopts one or more RNAi construct coating medical apparatus, this method comprises:

B) the RNAi construct with preparation is coated on medical device surface,

66. the method for claim 65, wherein medical apparatus be selected from that screw, plate, packing ring, suture line, prosthese anchoring device, hobnail, bail, electricity lead, valve, film, conduit, implantable vessel access port, storage blood bag, blood transfusion tube, central vein conduit, ductus arteriosus, blood vessel implant, IABP, heart valve, cardiovascular suture line, artificial heart, pacemaker, heart chamber auxiliary pump, device outside, hemofilter, hemodialysis assembly, hemoperfusion assembly, plasma exchange assembly and be suitable for unfolded filter in the blood vessel.

67. the method for claim 65, wherein medical apparatus is a support.

68. the method for claim 65, wherein the RNAi construct is little RNA interfering (siRNA).

69. the method for claim 68, wherein siRNA length is 19-30 base pair.

70. the method for claim 65, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

71. the method for claim 65, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

72. the method for claim 65, wherein the RNAi construct weakens and is selected from least a target gene expression in cell cycle protein dependent kinase, c-myb, c-myc, proliferating cell nuclear antigen (PCNA), transforming growth factor-beta (TGF-β), transcription factor nf κ B (NF-κ B), E2F, HER-2/neu, PKA, TGF-α, EGFR, TGF-β, IGFIR, P12, MDM2, BRCA, Bcl-2, VEGF, MDR, ferritin, TfR, IRE, C-fos, HSP27, C-raf and the metallothionein gene.

73. the method for claim 65, wherein RNAi construct reducer is expressed, and causes smooth muscle cell proliferation and/or migration to reduce.

74. a composition that comprises one or more RNAi constructs, wherein the RNAi construct is configured to be used for sending in the skin pericardium and passs to animal.

75. the composition of claim 74, wherein RNAi construct reducer is expressed, the blood vessel around causing reaching in the infarcted myocardium produces to be increased also/or reduce ischemic injury.

76. the composition of claim 74, wherein the RNAi construct is that whole body is available, and weakens one or more expression of gene in the pericardial cavity far-end cell.

77. the composition of claim 73, wherein the RNAi construct is configured to the supramolecular complex that comprises the multidimensional derivatized polymers.

78. the composition of claim 77, wherein supramolecular complex is formed by cationic polymers.

79. the composition of claim 78, wherein cationic polymers is selected from poly-(L) Methionin (PLL), polyaziridine (PEI), contains the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

80. the composition of claim 77, wherein supramolecular complex is by the polymer formation of cyclo-dextrin-modified.

81. the composition of claim 80, wherein supramolecular complex is formed by the polyaziridine of cyclo-dextrin-modified, and has the structure of following formula:

Wherein

And

82. the composition of claim 73, wherein the RNAi construct is packaged in liposome or associates with liposome.

83. the composition of claim 82, wherein liposome is to form the formed cationic-liposome of lipid by the positively charged ion vesica.

84. the composition of claim 82, wherein the mean diameter of liposome is less than about 200nm.

85. the composition of claim 73, wherein animal is human.

86. the composition of claim 73, wherein the RNAi construct is little RNA interfering (siRNA).

87. the composition of claim 86, wherein siRNA length is 19-30 base pair.

88. the composition of claim 73, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

89. the composition of claim 73, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

90. one kind is used for sending the method for passing one or more RNAi constructs in skin pericardium endosome, this method comprises the pericardial cavity that RNAi construct prescription is administered to animal, and wherein the amount of the RNAi construct of Cun Zaiing is enough to weaken one or more target gene expression of the animal body inner cell for the treatment of.

91. the method for claim 90, wherein pericardial cavity is used as sending of RNAi construct and passs storage at.

92. the method for claim 90, wherein the RNAi construct is sent by the part and passs to heart and peripheral vascular system thereof.

93. the method for claim 90, wherein the RNAi construct is used to reduce the propagation and/or the migration of smooth muscle cell.

94. the method for claim 90, wherein the RNAi construct is used to treat myocardial infarction.

95. the method for claim 90, wherein the RNAi construct is configured to the supramolecular complex that comprises the multidimensional derivatized polymers.

96. the method for claim 95, wherein supramolecular complex is formed by cationic polymers.

97. the method for claim 96, wherein cationic polymers is selected from poly-(L) Methionin (PLL), polyaziridine (PEI), contains the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

98. the method for claim 95, wherein supramolecular complex is by the polymer formation of cyclo-dextrin-modified.

99. the method for claim 98, wherein supramolecular complex is formed by the polyaziridine of cyclo-dextrin-modified, and has the structure of following formula:

Wherein

And

100. the method for claim 90, wherein the RNAi construct is packaged in liposome or associates with liposome.

101. the method for claim 100, wherein liposome is to form the formed cationic-liposome of lipid by the positively charged ion vesica.

102. the method for claim 100, wherein the mean diameter of liposome is less than about 200nm.

103. the method for claim 90, wherein animal is human.

104. the method for claim 90, wherein the RNAi construct is little RNA interfering (siRNA).

105. the method for claim 104, wherein siRNA length is 19-30 base pair.

106. the method for claim 90, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

107. the method for claim 90, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

108. a composition that comprises claim 90, and the pharmaceutical preparation of pharmaceutical acceptable carrier.

109. the pharmaceutical preparation of claim 108, wherein pharmaceutical acceptable carrier comprise or the salt of multiple acceptable salt, ester and these esters in one or more.

110. a pharmaceutical preparation that comprises claim 108, and instruct the drug packages that said preparation is given the specification sheets (literal and/or diagram) of human patients.

111. one kind comprises the composition that one or more are formulated in the RNAi construct in the liposome, is used for weakening the cells in vivo target gene expression by the RNA interference mechanism.

112. the composition of claim 111, wherein the RNAi construct is little RNA interfering (siRNA).

113. the composition of claim 112, wherein siRNA length is 19-30 base pair.

114. the composition of claim 111, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

115. the composition of claim 111, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

116. the composition of claim 111, wherein cell is a mammalian cell.

117. the composition of claim 116, wherein cell is the human cell.

118. the composition of claim 111, wherein liposome is to comprise that the positively charged ion vesica forms the cationic-liposome of lipid.

119. the composition of claim 111, wherein the mean diameter of liposome is less than about 200nm.

120. method that weakens target gene expression in patient's cell, this method comprises that the RNAi construct that will be formulated in the liposome gives the patient, dosage is enough to weaken target gene expression by the RNA interference mechanism, thereby changes growth, survival or the differentiation of described cell.

121. the method for claim 120, wherein the RNAi construct is little RNA interfering (siRNA).

122. the method for claim 121, wherein siRNA length is 19-30 base pair.

123. the method for claim 120, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

124. the method for claim 120, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

125. the method for claim 120, wherein cell is a mammalian cell.

126. the method for claim 125, wherein cell is the human cell.

127. the method for claim 120, wherein liposome is to comprise that the positively charged ion vesica forms the cationic-liposome of lipid.

128. the method for claim 120, wherein the mean diameter of liposome is less than about 200nm.

129. a composition that comprises claim 111, and the pharmaceutical preparation of pharmaceutical acceptable carrier.

130. the pharmaceutical preparation of claim 129, wherein pharmaceutical acceptable carrier comprise or the salt of multiple acceptable salt, ester and these esters in one or more.

131. a pharmaceutical preparation that comprises claim 129, and instruct the drug packages that said preparation is given the specification sheets (literal and/or diagram) of human patients.

132. a composition that comprises one or more RNAi constructs, this RNAi construct are used for electroporation by preparation and enter cells in vivo.

133. the composition of claim 132, wherein the RNAi construct is formulated in supramolecular complex or the liposome.

134. the composition of claim 132, wherein cell is an epithelial cell.

135. the composition of claim 132, wherein cell is the myocyte.

136. one kind is sent the method for passing the patient by electroporation with one or more RNAi constructs, this method comprises by electroporation and gives animal with the RNAi construct of capacity that wherein the RNAi construct weakens target gene expression in patient's cells in vivo.

137. the method for claim 136, wherein the RNAi construct is formulated in supramolecular complex or the liposome.

138. the method for claim 136, wherein cell is an epithelial cell.

139. the method for claim 136, wherein cell is the myocyte.

140. a composition that comprises claim 132, and the pharmaceutical preparation of pharmaceutical acceptable carrier.

141. the pharmaceutical preparation of claim 140, wherein pharmaceutical acceptable carrier comprise or the salt of multiple acceptable salt, ester and these esters in one or more.

142. a pharmaceutical preparation that comprises claim 140, and instruct the drug packages that said preparation is given the specification sheets (literal and/or diagram) of human patients.

143. composition that comprises the RNAi construct of one or more preparations, be used to suppress undesirable cell growth in the body, wherein by the RNA interference mechanism, the RNAi construct has reduced pair cell mitotic division and/or has stoped the requisite target gene expression of this apoptosis.

144. the composition of claim 143, wherein the RNAi construct is little RNA interfering (siRNA).

145. the composition of claim 144, wherein siRNA length is 19-30 base pair.

146. the composition of claim 143, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

147. the composition of claim 143, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

148. the composition of claim 146, wherein expression vector is selected from additive type expression vector, integrating expression vector or virus expression carrier.

149. the composition of claim 143, wherein the RNAi construct suppresses the propagation of cell.

150. the composition of claim 143, wherein the RNAi construct promotes the apoptosis of cell.

151. the composition of claim 143, wherein target gene is an oncogene.

152. the composition of claim 151, wherein oncogene is selected from c-myc, c-myb, mdm2, PKA-I, Abl-1, Bcl2, Ras, c-Raf kinases, CDC25 Phosphoric acid esterase, cyclin, cell cycle protein dependent kinase, Telomerase, PDGF/sis, erb-B, fos, jun, mos, src or Bcr/Abl fusion gene.

153. claim 143, any one composition of 149 and 150, wherein cell is a transformant.

154. the composition of claim 143, wherein the RNAi construct is used to treat the growth of hyperplasia sexual cell.

155. the composition of claim 154, wherein the RNAi construct is used to treat cancer.

156. the composition of claim 143, wherein the RNAi construct is used to suppress lymphocytic activation.

157. the composition of claim 156, wherein the RNAi construct is used to treat or the inflammatory diseases of epidemic prevention mediation.

158. the composition of claim 143, wherein the RNAi construct is used to suppress the propagation of smooth muscle cell.

159. the composition of claim 158, wherein the RNAi construct is used to treatment or prevention of restenosis.

160. the composition of claim 143, wherein the RNAi construct is used to suppress epithelial propagation.

161. the composition of claim 160, wherein the RNAi construct is used to cosmetic formulations.

162. the composition of claim 143, wherein the RNAi construct is formulated in the supramolecular complex.

163. the composition of claim 162, wherein supramolecular complex comprises at least a polymkeric substance.

164. the composition of claim 163, wherein polymkeric substance is the polymkeric substance that contains cyclodextrin.

165. the composition of claim 143, wherein the RNAi construct is packaged in liposome or associates with liposome.

166. the composition of claim 165, wherein liposome is to form the cationic-liposome that lipid forms by the positively charged ion vesica.

167. the composition of claim 165 wherein has typically less than the about basic single-size of 200nm with RNAi construct compound liposome.

168. the composition of claim 143, wherein animal is human.

169. method that suppresses undesirable cell growth in the body, this method comprises the RNAi construct of the preparation that gives the animal capacity, wherein by the RNA interference mechanism, the RNAi construct has reduced pair cell mitotic division and/or has stoped the requisite target gene expression of this apoptosis.

170. the method for claim 169, wherein the RNAi construct is little RNA interfering (siRNA).

171. the method for claim 170, wherein RNAi construct length is 19-30 base pair.

172. the method for claim 169, wherein the RNAi construct is the expression vector with encoding sequence, and described encoding sequence is transcribed generation, and one or more produce the transcription product of siRNA in the processing cell.

173. the method for claim 169, wherein the RNAi construct by be processed to the hairpin RNA of siRNA in the processing cell.

174. the method for claim 172, wherein expression vector is selected from additive type expression vector, integrating expression vector or virus expression carrier.

175. the method for claim 169, wherein the RNAi construct suppresses the propagation of cell.

176. the method for claim 169, wherein the RNAi construct promotes the apoptosis of cell.

177. the method for claim 169, wherein target gene is an oncogene.

178. the method for claim 169, wherein oncogene is selected from one of c-myc, c-myb, mdm2, PKA-I, Abl-1, Bcl2, Ras, c-Raf kinases, CDC25 Phosphoric acid esterase, cyclin, cell cycle protein dependent kinase, Telomerase, PDGF/sis, erb-B, fos, jun, mos, src and Bcr/Abl fusion gene.

179. claim 169, any one method of 175 and 176, wherein cell is a transformant.

180. the method for claim 169, wherein the RNAi construct is used to treat the growth of hyperplasia sexual cell.

181. the method for claim 180, wherein the RNAi construct is used to treat cancer.

182. the method for claim 169, wherein the RNAi construct is used to suppress lymphocytic activation.

183. the method for claim 182, wherein the RNAi construct is used to treat or the inflammatory diseases of epidemic prevention mediation.

184. the method for claim 169, wherein the RNAi construct is used to suppress the propagation of smooth muscle cell.

185. the method for claim 184, wherein the RNAi construct is used to treatment or prevention of restenosis.

186. the method for claim 169, wherein the RNAi construct is used to suppress epithelial propagation.

187. the method for claim 186, wherein the RNAi construct is used to cosmetic formulations.

188. the method for claim 169, wherein the RNAi construct is formulated in the supramolecular complex.

189. the method for claim 188, wherein supramolecular complex comprises at least a polymkeric substance.

190. the method for claim 189, wherein polymkeric substance is the polymkeric substance that contains cyclodextrin.

191. the method for claim 169, wherein the RNAi construct is packaged in liposome or associates with liposome.

192. the method for claim 191, wherein liposome is to form the cationic-liposome that lipid forms by the positively charged ion vesica.

193. the method for claim 191 wherein has typically less than the about basic single-size of 200nm with RNAi construct compound liposome.

194. the method for claim 169, wherein animal is human.

195. a composition that comprises claim 143, and the pharmaceutical preparation of pharmaceutical acceptable carrier.

196. the pharmaceutical preparation of claim 195, wherein pharmaceutical acceptable carrier is selected from the salt of pharmaceutically acceptable salt, ester and these esters.

197. a pharmaceutical preparation that comprises claim 195, and instruct the drug packages that said preparation is given the specification sheets of human patients.

198. a cosmetic formulations that comprises the composition of claim 143, wherein the RNAi construct suppresses epithelial growth or differentiation.

199. the method for an inducing cell death, this method comprise target cell double-stranded RNA in the donor, maybe can transcribe to have sufficient length to activate the expression vector of the double-stranded RNA that PKR replys in the target cell, this double-stranded RNA is configured to the part of supramolecular complex.

200. the method for claim 199, wherein the length of double-stranded RNA surpasses 35 base pairs.

201. the method for claim 200, wherein double-stranded RNA surpasses 75 Nucleotide.

202. the method for claim 199, wherein target cell is a mammalian cell.

203. the method for claim 199, wherein target cell is a transformant.

204. any one method among the claim 199-203, wherein supramolecular complex is the multidimensional derivatized polymers that comprises linear polymer.

205. any one method among the claim 199-203, wherein supramolecular complex is the multidimensional derivatized polymers that comprises branched chain polymer.

206. the method for claim 199, wherein supramolecular complex is formed by cationic polymers.

207. the method for claim 206, wherein cationic polymers is selected from poly-(L) Methionin (PLL), polyaziridine (PEI), contains the polymkeric substance (β CD-polymkeric substance) and the multipolymer thereof of beta-cyclodextrin.

208. the method for claim 199, wherein supramolecular complex is by the polymer formation of cyclo-dextrin-modified.

209. the method for claim 208, wherein supramolecular complex is formed by the polyaziridine of cyclo-dextrin-modified, and has the structure of following formula:

Wherein

And

210. a method of carrying out medicine commerce, this method comprises:

211. the method for claim 210 comprises foundation with the branch assembling system of this pharmaceutical preparation packing to be used to sell, and (randomly) sets up the replenish step of the selling party of this pharmaceutical preparation of marketing.

212. a method of carrying out medicine commerce, this method comprises: